

Weekly

April 10, 2009 / Vol. 58 / No. 13

# HIV-Associated Behaviors Among Injecting-Drug Users – 23 Cities, United States, May 2005–February 2006

Since the late 1980s, incidence of human immunodeficiency virus infection (HIV) has declined 80% among injecting-drug users (IDUs) in the United States; in 2006, an estimated 6,600 (12%) of new HIV infections occurred among IDUs (1). To assess HIV-associated behaviors among IDUs at risk for HIV infection, CDC analyzed data from the National HIV Behavioral Surveillance System (NHBS) collected during May 2005–February 2006 (the most recent data available). The results of that analysis indicated that, during that period, 31.8% of participating IDUs reported sharing syringes, and 62.6% had unprotected vaginal sex; 71.5% had been tested for HIV, and 27.4% had participated in an HIV behavioral intervention. These data can help guide local, state, and national prevention services tailored to IDUs at risk for HIV infections.

NHBS is an ongoing behavioral surveillance system, established by CDC in 2003 in cities where approximately 60% of all cases of acquired immunodeficiency syndrome (AIDS) had been reported. NHBS assesses trends in HIV risk behaviors, testing, and HIV prevention services among three groups: IDUs, men who have sex with men (MSM), and heterosexuals. NHBS data are collected in rotating cycles, approximately once every 3 years from each of the three groups; however, the groups are not mutually exclusive (e.g., MSM who inject drugs might be participants in both the MSM and IDU cycles).

For this report, interviews were conducted with IDUs in 23 metropolitan statistical areas,\* using respondent-driven sampling, a peer-referral sampling method (2). Recruitment

chains began in each city with fewer than 20 initial participants who either were referred from programs serving the local IDU community or were recruited by NHBS staff members through outreach. Initial participants who completed the interview were asked to recruit three other IDUs through the use of a coded coupon system to track the referrals. Recruitment continued for multiple waves of peer referrals; all participation was voluntary. Participants were paid \$25 for their interview time; those who recruited others were paid an additional \$10 for each eligible IDU they recruited to participate. Persons were eligible to participate if they had injected drugs during the preceding 12 months,<sup>†</sup> resided in the metropolitan statistical area where they were interviewed, were aged  $\geq 18$  years, and were able to give informed consent. Trained interviewers administered a standardized questionnaire in person, using a handheld computer; the survey took approximately 45 minutes to complete.

### INSIDE

- 333 Preliminary FoodNet Data on the Incidence of Infection with Pathogens Transmitted Commonly Through Food — 10 States, 2008
- 337 Cholera Outbreak Southern Sudan, 2007
- 342 Notice to Readers
- 343 QuickStats

<sup>\*</sup>Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Fort Lauderdale, Florida; Houston, Texas; Las Vegas, Nevada; Los Angeles, California; Miami, Florida; Nassau-Suffolk, New York; New Haven, Connecticut; New York, New York; Newark, New Jersey; Norfolk, Virginia; Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; San Juan, Puerto Rico; St. Louis, Missouri; and Seattle, Washington.

<sup>&</sup>lt;sup>†</sup> Interviewees were asked, "Have you ever in your life shot up or injected any drugs other than those prescribed for you? By shooting up, I mean any time you might have used drugs with a needle, either by mainlining, skin popping, or muscling." Those who said "yes" were then asked, "When was the last time you injected any drug? That is, how many days or months or years ago did you last inject?" Those who had injected during the 12 months preceding the date of the interview were eligible to participate.

330

### **MMWR**

The *MMWR* series of publications is published by the Coordinating Center for Health Information and Service, Centers for Disease Control and Prevention (CDC), U.S. Department of Health and Human Services, Atlanta, GA 30333.

**Suggested Citation:** Centers for Disease Control and Prevention. [Article title]. MMWR 2009;58:[inclusive page numbers].

### **Centers for Disease Control and Prevention**

Richard E. Besser, MD (Acting) Director Tanja Popovic, MD, PhD *Chief Science Officer* James W. Stephens, PhD Associate Director for Science Steven L. Solomon, MD Director, Coordinating Center for Health Information and Service Jay M. Bernhardt, PhD, MPH Director, National Center for Health Marketing Katherine L. Daniel, PhD Deputy Director, National Center for Health Marketing

#### **Editorial and Production Staff**

Frederic E. Shaw, MD, JD Editor, MMWR Series Elise M. Beltrami, MD, MPH Guest Editor, MMWR Series Susan F. Davis, MD (Acting) Assistant Editor, MMWR Series Robert A. Gunn, MD, MPH Associate Editor, MMWR Series Teresa F. Rutledge Managing Editor, MMWR Series Douglas W. Weatherwax Lead Technical Writer-Editor Donald G. Meadows, MA Jude C. Rutledge Writers-Editors Martha F. Boyd Lead Visual Information Specialist Malbea A. LaPete Stephen R. Spriggs Visual Information Specialists Kim L. Bright, MBA Quang M. Doan, MBA Phyllis H. King Information Technology Specialists

#### **Editorial Board**

William L. Roper, MD, MPH, Chapel Hill, NC, Chairman Virginia A. Caine, MD, Indianapolis, IN David W. Fleming, MD, Seattle, WA William E. Halperin, MD, DrPH, MPH, Newark, NJ Margaret A. Hamburg, MD, Washington, DC King K. Holmes, MD, PhD, Seattle, WA Deborah Holtzman, PhD, Atlanta, GA John K. Iglehart, Bethesda, MD Dennis G. Maki, MD, Madison, WI Sue Mallonee, MPH, Oklahoma City, OK Patricia Quinlisk, MD, MPH, Des Moines, IA Patrick L. Remington, MD, MPH, Madison, WI Barbara K. Rimer, DrPH, Chapel Hill, NC John V. Rullan, MD, MPH, San Juan, PR William Schaffner, MD, Nashville, TN Anne Schuchat, MD, Atlanta, GA Dixie E. Snider, MD, MPH, Atlanta, GA John W. Ward, MD, Atlanta, GA

For this report, data on eight selected HIV-associated behaviors were analyzed. Participants were asked whether, during the preceding 12 months, they 1) shared syringes; 2) shared injection equipment; 3) had vaginal sex<sup>§</sup>; 4) had unprotected vaginal sex; 5) had more than one opposite-sex partner; 6) were tested for HIV infection; and 7) participated in an individual or group HIV behavioral intervention; participants also were asked whether they 8) had ever been tested for hepatitis C virus (HCV) infection.<sup>9</sup> Data from each metropolitan statistical area were analyzed using a respondent-driven sampling analysis program that produces estimates adjusted for differences in peer recruitment patterns and size of participant IDU peer networks (3). Results from these analyses were aggregated and weighted by the size of the IDU population in each metropolitan statistical area (4) to obtain an overall estimated prevalence for each behavior.

During May 2005–February 2006, a total of 13,519 persons were recruited to participate; of these, 1,563 (11.6%) were found ineligible, and 46 had missing recruitment information. Among the remaining 11,910 participants, data for 1,609 were excluded: 881 who already knew they had HIV infection, 334 whose data were lost during electronic upload, 288 initial participants (whose responses were excluded as part of the respondent-driven sampling methodology), 68 who could not be identified as either male or female, and 38 who gave responses with questionable validity. Data for the remaining 10,301 participants were used for this report. Overall, by demographic characteristic, the highest percentages of participants were men (66.7%), non-Hispanic blacks (47.1%), and persons aged 45–54 years (38.0%).

Among the participating IDUs, 31.8% reported sharing syringes, and 33.4% reported sharing injection equipment during the preceding 12 months (Table). Syringes were shared most commonly among non-Hispanic white IDUs (40.2%) and persons aged 25–34 years (38.6%).

Overall, 81.7% of the IDUs reporting having vaginal sex, and 62.6% reported having unprotected vaginal sex; 47.2% had more than one opposite-sex partner during the preceding 12 months. The prevalence of having unprotected vaginal sex was highest among those aged 18–24 years (67.4%). The prevalence of having more than one opposite-sex partner was highest among those aged 25–34 years (57.6%) (Table).

<sup>§</sup> For this report, data on anal sex were not analyzed.

Sharing syringes was defined as "using needles that might have already been used by someone else," and sharing injection equipment was defined as using equipment such as cookers, cottons, or water used to rinse needles or prepare drugs "that someone else used." Unprotected vaginal sex was defined as "sex without a condom." Participating in an individual or group HIV behavioral intervention did not include counseling received as part of an HIV test. Testing for HCV infection was measured as ever tested or ever received a diagnosis of hepatitis C.

Vol. 58 / No. 13

#### **MMWR**

TABLE. Estimated percentage<sup>\*</sup> of injecting-drug users (IDUs) engaging in selected behaviors associated with human immunodeficiency virus (HIV) infection<sup>†</sup> during the preceding 12 months, by sex, race/ethnicity, and age group — National HIV Behavioral Surveillance System, 23 cities,<sup>§</sup> United States, May 2005–February 2006

	Shared syringes	Shared injection equipment	Had vaginal sex	Had unprotected vaginal sex	Had more than one opposite-sex partner	Tested for HIV infection	Participated in HIV behavioral intervention	Tested for hepatitis C
Characteristic	%	%	%	%	%	%	%	%
	(SE¹)	(SE)	(SE)	(SE)	(SE)	(SE)	(SE)	(SE)
Overall	31.8	33.4	81.7	62.6	47.2	71.5	27.4	72.2
	(4.9)	(4.9)	(4.8)	(5.2)	(5.1)	(5.0)	(4.9)	(5.0)
Sex	<b>、</b>	( )	( )	( )	( )	( )	ζ,	( )
Men	32.1	36.4	82.7	62.8	50.8	69.8	26.3	73.8
	(5.3)	(5.7)	(5.0)	(5.6)	(5.6)	(5.4)	(5.1)	(5.4)
Women	31.6	30.5	79.7	62.3	40.1	74.5	29.8	67.8
	(6.6)	(6.4)	(6.5)	(6.9)	(6.7)	(6.4)	(6.6)	(7.4)
Race/Ethnicity								
White, non-Hispanic	40.2	37.0	80.6	63.9	48.4	68.6	21.7	75.2
	(6.6)	(6.6)	(6.0)	(6.6)	(6.7)	(6.7)	(5.9)	(6.3)
Black, non-Hispanic	29.1	33.1	84.6	64.0	50.9	71.4	27.9	68.6
	(5.4)	(5.5)	(4.9)	(5.6)	(5.7)	(5.4)	(5.3)	(5.5)
Hispanic	28.9	29.7	75.3	58.4	38.8	73.6	31.6	75.4
	(10.0)	(9.7)	(10.5)	(10.9)	(10.7)	(10.1)	(9.9)	(10.1)
Other**	34.8	39.7	83.0	59.5	46.0	69.9	29.5	75.8
	(11.7)	(12.1)	(10.3)	(12.1)	(12.1)	(12.0)	(11.3)	(10.9)
Age group (yrs)	<b>、</b>	( )			· · ·			. ,
18–24	34.5	29.7	88.1	67.4	55.7	83.0	24.5	63.0
	(9.7)	(8.0)	(8.3)	(10.5)	(10.6)	(8.5)	(9.3)	(10.5)
25–34	38.6	33.8	86.8	64.7	57.6	75.7	25.4	66.5
	(7.5)	(7.3)	(6.6)	(7.8)	(7.6)	(6.7)	(7.1)	(7.4)
35–44	31.8	33.8	85.0	66.9	48.4	71.9	29.6	67.1
	(6.5)	(6.6)	(6.3)	(6.9)	(6.9)	(6.8)	(6.8)	(7.0)
45–54	32.5	35.2	80.4	62.2	44.6	68.5	28.3	76.9
	(6.2)	(6.5)	(6.1)	(6.6)	(6.6)	(6.5)	(6.2)	(6.1)
<u>≥</u> 55	22.4	29.0	70.5	49.2	36.5	70.0	22.9	79.4
	(7.9)	(8.9)	(9.4)	(9.1)	(8.9)	(9.4)	(8.0)	(7.9)

 \* Percentages were weighted to adjust for differences in recruitment, the size of participant IDU peer networks, and the size of the IDU population in each city.
 † Atlanta, Georgia; Baltimore, Maryland; Boston, Massachusetts; Chicago, Illinois; Dallas, Texas; Denver, Colorado; Detroit, Michigan; Fort Lauderdale, Florida; Houston, Texas; Las Vegas, Nevada; Los Angeles, California; Miami, Florida; Nassau-Suffolk, New York; New Haven, Connecticut; New York, New York; Newark, New Jersey; Norfolk, Virginia; Philadelphia, Pennsylvania; San Diego, California; San Francisco, California; San Juan, Puerto Rico; St. Louis, Missouri; and Seattle, Washington.

<sup>§</sup> Sharing syringes was defined as "using needles that might have already been used by someone else," and sharing injection equipment was defined as using equipment such as cookers, cottons, or water used to rinse needles or prepare drugs "that someone else used." Unprotected vaginal sex was defined as "sex without a condom." Persons tested for HIV infection include those with results that were negative, indeterminate, or unknown. Participating in an individual or group HIV behavioral intervention did not include counseling received as part of an HIV test. Testing for hepatitis C virus infection was measured as ever tested or ever received a diagnosis of hepatitis C.

Standard error.

\*\* Includes American Indian/Alaska Natives, Asians, Native Hawaiian or other Pacific Islanders, persons of multiple race, and those for whom race/ethnicity information was missing.

During the 12 months preceding their interviews, 71.5% of participants had been tested for HIV infection; the prevalence of testing was lowest among men (69.8%), non-Hispanic whites (68.6%), and persons aged 45–54 years (68.5%). Among the IDUs, 27.4% reported participating in an individual or group HIV behavioral intervention; such participation was least common among non-Hispanic whites (21.7%). HCV testing or diagnosis had been received by 72.2% of participants at some time in their lives; HCV testing was least common among those aged 18–24 years (63.0%) (Table). **Reported by:** A Lansky, PhD, A Drake, MPH, HT Pham, MPH, Div of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, CDC.

**Editorial Note:** NHBS provides the first national estimates of certain HIV-associated behaviors among IDUs in 23 cities with high AIDS prevalence. The finding that approximately one third of participants reported sharing syringes or injection equipment (31.8% and 33.4%, respectively) underscores the need to continue to focus HIV prevention strategies on these behaviors despite declines in HIV incidence among IDUs (1). These data are consistent with data on sharing syringes

331

### MMWR

reported in 2007 from a multi-city study (5). However, the NHBS data also indicate that approximately half of participants had unprotected vaginal sex (62.6%) or multiple opposite-sex partners (47.2%), suggesting that a substantial proportion of IDUs are at risk for acquiring HIV infection through their sexual behavior in addition to their drug use practices.

Behavioral interventions have been shown to reduce risk behaviors among IDUs (6). However, only 27.4% of NHBS participants had participated in individual or group HIV behavioral interventions during the preceding 12 months. Among racial/ethnic populations, HIV testing and participation in behavioral interventions were more common among non-Hispanic blacks and Hispanics, persons for whom HIV incidence rates are disproportionately high (I) and for whom interventions are most needed. Although IDUs aged 18-24 years had the highest prevalence of receiving HIV testing, they had the lowest prevalence of ever being tested for HCV. National recommendations for prevention and control of HCV infection call for risk-reduction counseling and screening of persons at risk for HCV infection, including IDUs (7). To increase the percentage of HIV-positive persons who know they have HIV infection, IDUs should have an HIV test at least annually (8).

The findings in this report are subject to at least three limitations. First, because no standard exists for obtaining probability samples of IDUs, the representativeness of the NHBS sample cannot be determined; although respondent-driven sampling adjusts for some biases, other factors (e.g., not every IDU network was sampled in each city) might have affected the representativeness of the sample. Second, findings from the 23 cities in this study might not be generalizable to all other cities or states in the United States. Finally, because the questionnaire was administered in person by an interviewer, some participants might not have accurately reported their behavior because of social desirability bias.

The NHBS data in this report underscore the need to continue current public health strategies (e.g., ready IDU access to HIV testing, sterile syringes, and condoms) and expand the reach of effective behavioral interventions that focus on the HIV risks of sharing syringes and other injection equipment and engaging in high-risk sexual behavior. Because IDUs are at high risk for numerous bloodborne and sexually transmitted infections, they are prime candidates for integrated health services (9) that provide disease prevention counseling and relevant screening (or vaccination) for hepatitis, sexually transmitted diseases, tuberculosis, or HIV, whenever they seek health care. Certain state and local syringe exchange programs already have expanded their scopes to include these types of integrated services (10). Providing comprehensive services to IDUs can help reduce the spread of bloodborne infections and increase access to health care, providing an effective approach to the spread of disease for the entire population (*6*).

#### **Acknowledgments**

This report is based, in part, on contributions by local NHBS staff members, including the following principal investigators: L Shouse, Georgia Div of Human Resources; C Flynn, Maryland Dept of Health and Mental Hygiene; E Rubinstein, Massachusetts Dept of Public Health; C Ciesielski, Chicago Dept of Public Health; S Melville, Texas Dept of State Health Svcs; B Dillon, Colorado Dept of Health and Environment; A Roome, Connecticut Dept of Health; E Mokotoff, Michigan Dept of Community Health; M Wolverton, Houston Dept of Health, Texas; D Crockett, Nevada Dept of Public Health; T Bingham, Los Angeles County Dept of Public Health, California; M LaLota, Florida Dept of Health; C Nemeth, New York Dept of Health; C Murrill, New York City Dept of Health and Mental Hygiene, New York; H Cross, New Jersey Dept of Health and Senior Svcs; D Bensen, Virginia Dept of Public Health; K Brady, Philadelphia Dept of Health, Pennsylvania; A Ritieni, California Dept of Health; HF Raymond, San Francisco Dept of Public Health; SM De Leon, Puerto Rico Dept of Health; Y Friedberg, Missouri Dept of Health; and M Courogen, Washington Dept of Health. DD Heckathorn, Cornell Univ, Ithaca, New York.

#### References

- 1. Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA 2008;300:520–9.
- Lansky A, Abdul-Quader AS, Cribbin M, et al. Development of an HIV behavioral surveillance system for injecting drug users: the National HIV Behavioral Surveillance System. Public Health Rep 2007;122(Suppl 1):48–55.
- Salganik MJ, Heckathorn, DD. Sampling and estimation in hidden populations using respondent-driven sampling. Sociological Methodology 2004;34:193–239.
- Brady JE, Friedman SR, Cooper HL, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to 2002. J Urban Health 2008;85:323–51.
- Des Jarlais DC, Braine N, Yi H, Turner C. Residual injection risk behavior, HIV infection, and the evaluation of syringe exchange programs. AIDS Educ Prev 2007;19:111–23.
- 6. Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med 2008;70:606–11.
- 7. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR 1998;47(No. RR-19).
- 8. CDC. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR 2006;55(No. RR-14).
- 9. Ward JW, Fenton KA. CDC and progress toward integration of HIV, STD, and viral hepatitis prevention. Public Health Rep 2007;122 (Suppl 2):99–101.
- CDC. Syringe exchange programs—United States, 2005. MMWR 2007;56:1164–7.

# Preliminary FoodNet Data on the Incidence of Infection with Pathogens Transmitted Commonly Through Food – 10 States, 2008

Foodborne diseases remain an important public health problem in the United States. The Foodborne Diseases Active Surveillance Network (FoodNet) of CDC's Emerging Infections Program collects data from 10 U.S. states\* on diseases caused by enteric pathogens transmitted commonly through food. FoodNet is an active, population-based surveillance system for these laboratory-confirmed infections (1). This report describes preliminary surveillance data for 2008 and trends since 1996. In 2008, the estimated incidence of infections caused by Campylobacter, Cryptosporidium, Cyclospora, Listeria, Shiga toxin-producing Escherichia coli (STEC) O157, Salmonella, Shigella, Vibrio, and Yersinia did not change significantly when compared with the preceding 3 years. For most infections, incidence was highest among children aged <4 years, whereas the percentage of persons hospitalized and the case fatality rate were highest among persons aged  $\geq 50$ years. None of the Healthy People 2010 targets for reduction of foodborne pathogens (objective 10-1) (2) were reached in 2008. The lack of recent progress points to gaps in the current food safety system and the need to continue to develop and evaluate food safety practices as food moves from the farm to the table.

# **Surveillance Methods**

FoodNet has conducted active, population-based surveillance for laboratory-confirmed cases of infection caused by Campylobacter, Listeria, Salmonella, STEC O157, Shigella, Vibrio, and Yersinia since 1996, Cryptosporidium and Cyclospora since 1997, and STEC non-O157 since 2000 in 10 participating states. FoodNet personnel actively contact clinical laboratories (on a regular basis, depending on the size of the laboratory) to ascertain laboratory-confirmed cases of infection occurring within the surveillance area (1). In 2004, FoodNet began collecting data regarding which laboratory-confirmed infections were associated with outbreaks of Salmonella and STEC O157. FoodNet also conducts surveillance for hemolytic uremic syndrome (HUS), a complication of STEC infection characterized by renal failure and microangiopathic hemolytic anemia, through a network of pediatric nephrologists and infection-control practitioners, and validates diagnoses through reviews of hospital discharge data. Because of the time required to review hospital records, this report contains preliminary HUS data for 2007, the most recent data available (1).

Preliminary incidence rates for 2008 were calculated by dividing the number of laboratory-confirmed infections by U.S. Census Bureau population estimates for 2007. The FoodNet surveillance population was approximately 46 million persons (15% of the U.S. population) in 2007. Final incidence rates will be reported when population estimates for 2008 are available.

## **Surveillance Results**

In 2008, a total of 18,499 laboratory-confirmed cases of infection in FoodNet surveillance areas were identified. The number of infections and incidence per 100,000 population were reported as follows: *Salmonella* (7,444; 16.20), *Campylobacter* (5,825; 12.68), *Shigella* (3,029; 6.59), *Cryptosporidium* (1,036; 2.25), STEC O157 (513; 1.12), STEC non-O157 (205; 0.45), *Yersinia* (164; 0.36), *Listeria* (135; 0.29), *Vibrio* (131; 0.29), and *Cyclospora* (17; 0.04). Substantial variation in incidence rates occurred among surveillance areas (Table 1). Among all age groups (<4 years, 4–11 years, 12–19 years, 20–49 years, and  $\geq$ 50 years)<sup>†</sup>, the highest incidence occurred among children aged <4 years for all infections except those caused by *Cyclospora* and *Vibrio* (Table 2).

Among age groups of persons infected with the following pathogens, the percentage of persons hospitalized was highest in persons aged  $\geq$ 50 years: *Listeria* (86.2%), STEC O157 (53.3%), *Vibrio* (45.6%), *Salmonella* (40.0%), *Yersinia* (37.5%), *Shigella* (27.9%), *Cryptosporidium* (24.5%), and *Campylobacter* (20.5%). Among age groups of persons infected with the following pathogens, the case fatality rate (CFR) was highest in persons aged  $\geq$ 50 years: *Listeria* (19.5%), *Vibrio* (7.4%), *Salmonella* (1.3%), *Shigella* (0.4%), and *Campylobacter* (0.4%). For infection with STEC O157, the CFR was highest among children aged <4 years (2.8%); for infection with *Cryptosporidium* and *Yersinia*, the CFR was highest in persons aged 20–49 years (1.3% and 3.0%, respectively).

Among 6,750 (91%) *Salmonella* isolates serotyped, 10 serotypes accounted for 73% of infections: Enteritidis, 1,356 (20.1%); Typhimurium, 1,077 (16.0%); Newport, 681 (10.1%); Javiana, 423 (6.3%); Saintpaul, 403 (6.0%); I 4,[5],12:i:-, 269 (4.0%); Muenchen, 213 (3.2%); Heidelberg, 198 (2.9%); Montevideo, 194 (2.9%); and Braenderup, 108 (1.6%). Among 131 (92%) *Vibrio* isolates for which the species was identified, 72 (55.0%) were *parahaemolyticus*, 19 (14.5%)

<sup>\*</sup> Connecticut, Georgia, Maryland, Minnesota, New Mexico, Oregon, Tennessee, and selected counties in California, Colorado, and New York.

<sup>&</sup>lt;sup>†</sup> Age groups correspond to those defined by CDC's Healthy People in Every Stage of Life goals. Available at http://www.cdc.gov/osi/goals/people.html.

TABLE 1. Incidence\* of laboratory-confirmed bacterial and parasitic infection in 2008<sup>†</sup> and postdiarrheal hemolytic uremic syndrome (HUS) in 2007, by site and pathogen, compared with national health objectives<sup>§</sup> — Foodborne Diseases Active Surveillance Network, United States

Pathogen	California	Colorado	Connecticut	Georgia	Maryland	Minnesota	New Mexico	New York	Oregon	Tennessee	Overall 2008	National health objective§
Bacteria												
Campylobacter	30.23	14.36	15.13	7.15	6.66	16.97	17.97	11.20	18.20	7.68	12.68	12.30
Listeria	0.65	0.15	0.46	0.27	0.30	0.13	0.25	0.45	0.16	0.23	0.29	0.24
Salmonella	14.62	12.48	14.10	23.97	15.02	14.53	26.40	10.15	10.59	14.63	16.20	6.80
Shigella	4.83	3.15	1.14	11.51	2.05	5.96	8.02	0.77	1.97	15.56	6.59	1
STEC** 0157	1.14	3.04	0.74	0.44	0.59	2.27	0.81	1.20	1.49	0.84	1.12	1.00
STEC non-O157	0.06	0.89	0.49	0.26	0.55	0.98	1.47	0.40	0.13	0.06	0.45	_
Vibrio	0.65	0.15	0.40	0.20	0.59	0.15	0.10	0.19	0.32	0.16	0.29	_
Yersinia	0.34	0.26	0.43	0.47	0.23	0.33	0.15	0.45	0.40	0.31	0.36	_
Parasites												
Cryptosporidium	1.32	1.00	1.17	2.66	0.94	4.50	8.83	2.65	1.44	0.70	2.25	_
Cyclospora	0.00	0.00	0.11	0.02	0.05	0.06	0.10	0.00	0.00	0.05	0.04	_
HUS <sup>††</sup>	2.43	0.98	0.47	1.08	0.27	2.83	_	1.31	2.54	3.91	1.75	0.90
Surveillance												
population (millions)	3.25	2.70	3.50	9.54	5.62	5.20	1.97	4.27	3.75	6.16	45.95	

\* Per 100,000 population. † Data for 2008 are preliminary.

§ Current Healthy People 2010 objective 10-1 targets for incidence of Campylobacter, Salmonella, Shiga toxin-producing Escherichia coli O157, and Listeria infections, and HUS. <sup>1</sup>No national health objective exists for these pathogens.

\*\* Shiga toxin-producing Escherichia coli.

11 Incidence of postdiarrheal HUS in children aged <5 years; denominator is surveillance population aged <5 years in sites that conduct hospital discharge data review (New Mexico excluded).

TABLE 2. Incidence\* of laboratory-confirmed bacterial and parasitic infections in 2008,<sup>†</sup> by age group — Foodborne **Diseases Active Surveillance Network, United States** 

		Age	e group (y	oup (yrs) <sup>§</sup>					
Pathogen	<4	4–11	12–19	20–49	<u>≥</u> 50				
Bacteria									
Campylobacter	28.54	10.06	9.37	12.40	12.27				
Listeria	0.76	1	_	0.15	0.63				
Salmonella	74.65	19.28	11.29	11.41	13.09				
Shigella	27.86	25.67	2.99	3.61	1.70				
STEC** 0157	4.24	2.57	1.51	0.59	0.65				
STEC non-O157	2.52	0.86	0.63	0.25	0.14				
Vibrio	0.08	0.04	0.10	0.27	0.49				
Yersinia	2.24	0.25	0.30	0.17	0.35				
Parasites									
Cryptosporidium	6.08	3.05	1.73	2.32	1.38				
Cyclospora	—	—	0.04	0.03	0.06				

\* Per 100,000 population.

<sup>†</sup> Data for 2008 are preliminary.

§ Age groups defined in CDC's Healthy People in Every Stage of Life goals, available at http://www.cdc.gov/osi/goals/people.html.

<sup>¶</sup> No cases reported.

\*\* Shiga toxin-producing Escherichia coli.


were vulnificus, and eight (6.1%) were alginolyticus. Among 205 STEC non-O157 isolates tested for O antigen determination, 185 (90%) had an identifiable O antigen, most commonly O26 (28.1%), O103 (27.0%), or O111 (19.5%).

In 2007, FoodNet identified 77 cases of postdiarrheal HUS in persons aged <18 years (0.73 cases per 100,000 children). Among these 77 cases, 52 (68%) occurred in children aged <5 years (1.75 cases per 100,000 children).

# **Comparison with Previous Years**

A main-effects, log-linear Poisson regression model (negative binomial) was used to estimate statistically significant changes in incidence of infections in 2008 compared with previous years. This model accounts for site-to-site variation and the change in population in FoodNet surveillance areas over time (1). The average annual incidence for the preceding 3 years (2005–2007) and the first 3 years of surveillance (1996–1998) were used for comparison. The estimated change in incidence between 2008 and the comparison periods was calculated with 95% confidence intervals (CIs). For HUS surveillance, the average annual incidence for 2004-2006 was used as the comparison period. Changes over time were not analyzed for STEC non-O157, partly because changes in clinical laboratory practices, such as increases in Shiga toxin testing with enzyme immunoassay, likely affected reporting (3).

The estimated incidence of Campylobacter, Listeria, Salmonella, Shigella, STEC O157, Vibrio, Yersinia, and Cryptosporidium infections did not change significantly compared with the preceding 3 years (Figure 1). The apparent increase in Salmonella infections was not significant (CI = 0%-12%). Among the 10 most common Salmonella serotype infections, the incidence of Enteritidis increased 19% (CI = 3%-39%), Saintpaul increased 182% (CI = 112%-274%), and Heidelberg decreased 28% (CI = 12% - 41%); the incidence of the other seven serotypes did not change significantly. Trends for Cyclospora infection were not calculated because of low incidence across sites and years. The estimated incidence of postdiarrheal HUS in





\* Data for 2008 are preliminary.

<sup>†</sup> No significant change = 95% confidence interval is both above and below the no change line; significant increase = estimate and entire 95% confidence interval are above the no change line; significant decrease = estimate and entire 95% confidence interval are below the no change line.
§ Shiga toxin-producing Escherichia coli.


children aged <5 years in 2007 did not change significantly compared with 2004–2006.

The lack of significant change in recent years is in contrast to trends from 1996, when FoodNet surveillance began, to 2004 (Figure 2). By 2008, in comparison with 1996–1998, modeled relative rates of infection with *Yersinia* had decreased 48% (CI = 35%–59%), *Shigella* had decreased 40% (CI = 15%–58%), *Listeria* had decreased 36% (CI = 20%–49%), *Campylobacter* had decreased 32% (CI = 27%–37%), and STEC O157 had decreased 25% (CI = 8%–39%), but *Vibrio* had increased 47% (CI = 9%–99%). The estimated incidence of infection with *Cryptosporidium* and *Salmonella* did not change significantly over this period.

# **Outbreak-Associated Cases of Infection**

In 2008, outbreak-associated infections accounted for 132 (25.7%) of STEC O157 cases and 547 (7.4%) of *Salmonella* cases. Two large multistate outbreaks of *Salmonella* infections that included FoodNet sites were investigated in 2008: an outbreak of *S.* Saintpaul infections associated with imported produce (4) and an outbreak of *S*. Typhimurium infections associated with peanut butter and peanut butter–containing products (5).

FIGURE 2. Relative rates of laboratory-confirmed infections with *Vibrio, Salmonella*, STEC\* 0157, *Campylobacter*, and *Listeria* compared with 1996–1998 rates, by year — Foodborne Diseases Active Surveillance Network, United States, 1996–2008<sup>†</sup>



\* Shiga toxin-producing Escherichia coli.

<sup>+</sup> The position of each line indicates the relative change in the incidence of that pathogen compared with 1996–1998. The actual incidences of these infections can differ. Data for 2008 are preliminary.

**Reported by:** D Vugia, MD, California Dept of Public Health. A Cronquist, MPH, Colorado Dept of Public Health and Environment. M Cartter, MD, Connecticut Dept of Public Health. M Tobin-D'Angelo, MD, Div of Public Health, Georgia Dept of Human Resources. D Blythe, MD, Maryland Dept of Health and Mental Hygiene. K Smith, DVM, Minnesota Dept of Health. S Lathrop, PhD, New Mexico Dept of Health. D Morse, MD, New York State Dept of Health. P Cieslak, MD, Oregon Public Health Div. J Dunn, DVM, Tennessee Dept of Health. KG Holt, DVM, Food Safety and Inspection Svc, US Dept of Agriculture. Center for Food Safety and Applied Nutrition, Food and Drug Admin. OL Henao, PhD, RM Hoekstra, PhD, FJ Angulo, DVM, PM Griffin, MD, RV Tauxe, MD, Div of Foodborne, Bacterial, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases; KK Trivedi, MD, EIS Officer, CDC.

Editorial Note: Despite numerous activities aimed at preventing foodborne human infections, including the initiation of new control measures after the identification of new vehicles of transmission (e.g., peanut butter-containing products), progress toward the national health objectives has plateaued, suggesting that fundamental problems with bacterial and parasitic contamination are not being resolved. Although significant declines in the incidence of certain pathogens have occurred since establishment of FoodNet, these all occurred before 2004. Of the four pathogens with current *Healthy People 2010* targets, Salmonella, with an incidence rate of 16.2 cases per 100,000 in 2008, is farthest from its target for 2010 (6.8). The lack of recent progress toward the national health objective targets and the occurrence of large multistate outbreaks point to gaps in the current food safety system and the need to continue to develop and evaluate food safety practices as food moves from the farm to the table.

Efforts to reduce contamination of meat, poultry, produce, and other foods are ongoing. In 2006, the U.S. Department of Agriculture's Food Safety and Inspection Service implemented a Salmonella initiative program to prevent Salmonella contamination of meat and poultry.§ Industry response to the program has resulted in a decrease in the percent-positive rate for Salmonella in raw broiler chicken from 11.4% in 2006 to 7.3% in 2008 (6). Additionally, the percentage of broiler chicken slaughter establishments with Salmonella contamination rates at half or below half of the performance standard increased from 49% in 2006 to 82% in 2008 (2010 target is 90%) (6). However, the percentage of ground beef samples yielding STEC O157 increased from 0.24% in 2007 to 0.47% in 2008 (7); whether the increase was related to focused sampling of higher risk facilities or improved laboratory detection, or whether the microbial load was actually higher, is unknown. In August 2008, the Food and Drug Administration (FDA) published a rule allowing irradiation of fresh iceberg lettuce and fresh spinach to help protect consumers from *Salmonella* and STEC O157; FDA also piloted an advanced screening system to identify food safety threats at all U.S. borders.<sup>¶</sup>

Enhanced and food-specific measures are needed to 1) control or eliminate pathogens in domestic and imported food; 2) reduce or prevent contamination during growing, harvesting, and processing; and 3) continue the education of restaurant workers and consumers about risks and prevention measures. In particular, continued efforts are needed to understand how contamination of fresh produce and processed foods occurs and to develop and implement measures that reduce it. More outbreaks can be recognized and their causative foods identified with rapid and complete subtyping of pathogens and with rapid standardized interviews of ill persons and appropriately selected controls.

The reported incidence of *Campylobacter*, *Salmonella*, and STEC O157 infections varies substantially by site. For example, incidence of *Campylobacter* is highest in California, incidence of *Salmonella* is highest in New Mexico and Georgia, and incidence of STEC O157 is highest in Colorado. Previous FoodNet studies suggest that even after controlling for laboratory testing practices, site-to-site variation in disease incidence reflects regional differences in exposures, which might include the consumption of contaminated food or exposure through other routes of transmission (*8,9*).

The reported incidence of *Campylobacter*, *Cryptosporidium*, *Listeria*, *Salmonella*, *Shigella*, STEC O157, and *Yersinia* infections remains highest among children aged <4 years. For most pathogens under surveillance, persons aged  $\geq$ 50 years are at greater risk than are other age groups for hospitalization and death, making aggressive diagnosis and treatment especially important in this age group.

The findings in this report are subject to at least four limitations. First, because FoodNet relies on laboratory diagnoses, changing laboratory practices might affect the reported incidence of some pathogens. For example, fewer laboratoryconfirmed infections might be reported as a result of increased use of nonculture tests. Second, many foodborne illnesses (e.g., norovirus infection) are not reported to FoodNet because these pathogens are not identified routinely in clinical laboratories. Third, differences in health-care seeking behaviors between age groups might contribute to a much higher incidence of reported illness in certain age groups (e.g., young children and older persons) (10). Finally, although the FoodNet population is similar demographically to the U.S. population, the findings might not be generalizable (1).

<sup>§</sup> Additional information about the Salmonella verification sampling program is available at http://www.fsis.usda.gov/oppde/rdad/frpubs/04-026n.pdf.

<sup>&</sup>lt;sup>9</sup> Additional information about the FDA Food Protection Plan is available at http://www.fda.gov/oc/initiatives/advance/food/progressreport1108.html.

Consumers can reduce their risk for foodborne illness by following safe food-handling and preparation recommendations and by avoiding consumption of unpasteurized milk, raw or undercooked oysters, or other raw or undercooked foods of animal origin such as eggs, ground beef, and poultry. Risk also can be decreased by choosing pasteurized eggs, high pressure-treated oysters, and irradiated produce. Everyone should wash hands before and after contact with raw meat, raw foods derived from animal products, and animals and their environments. More detailed information on food safety practices is available at http://www.foodsafety.gov and http:// www.fightbac.org.

#### References

- Scallan E. Activities, achievements, and lessons learned during the first 10 years of the Foodborne Diseases Active Surveillance Network: 1996–2005. Clin Infect Dis 2007;44:718–25.
- 2. US Department of Health and Human Services. Food safety. Objective 10-1: Reduce infections caused by key foodborne pathogens. Healthy people 2010 (conference ed, in 2 vols). Washington, DC: US Department of Health and Human Services; 2000. Available at http:// www.healthypeople.gov/document/pdf/volume1/10food.pdf.
- 3. CDC. Laboratory-confirmed non-O157 Shiga toxin-producing Escherichia coli—Connecticut, 2000–2005. MMWR 2007;56:29–31.
- CDC. Outbreak of *Salmonella* serotype Saintpaul infections associated with multiple raw produce items—United States, 2008. MMWR 2008;57:929–34.
- CDC. Multistate outbreak of *Salmonella* infections associated with peanut butter and peanut butter-containing products—United States, 2008–2009. MMWR 2009;58:1–6.
- 6. US Department of Agriculture. *Salmonella* verification testing program for raw meat and poultry. Washington, DC: US Department of Agriculture, Food Safety and Inspection Service; 2009. Available at http://www.fsis.usda.gov/science/microbiology/index.asp.
- 7. US Department of Agriculture. Testing of raw ground beef and raw ground beef component samples for *E. coli* O157:H7: year-to-date totals. Washington, DC: US Department of Agriculture, Food Safety and Inspection Service; 2009. Available at http://www.fsis.usda.gov/ science/ecoli\_raw\_beef\_testing\_data\_ytd/index.asp.
- Bender JB, Smith KE, McNees AA, et al. Factors affecting surveillance data on *Escherichia coli* O157 infections collected from FoodNet sites, 1996–1999. Clin Infect Dis 2004;38(Suppl 3):S157–64.
- Ailes E, Demma L, Hurd S, et al. Continued decline in the incidence of *Campylobacter* infections, FoodNet 1996–2006. Foodborne Pathog Dis 2008;5:329–37.
- Scallan E, Jones TF, Cronquist A, et al. Factors associated with seeking medical care and submitting a stool sample in estimating the burden of foodborne illness. Foodborne Pathog Dis 2006;3:432–8.

# Cholera Outbreak – Southern Sudan, 2007

*Vibrio cholerae* causes cholera, an acute infectious diarrheal disease that can result in death without appropriate therapy, depending on the severity of the disease (1). War, poverty, inadequate sanitation, and large numbers of refugees and internally displaced persons (IDPs) are major precursors to cholera

outbreaks (2). In 2005, Southern Sudan ended its 22-year civil war with North Sudan; as a result, IDPs and refugees are returning to the south (3,4). During April–June 2007, investigators from the Southern Sudan Field Epidemiology and Laboratory Training Program (SS-FELTP) and CDC investigated a cholera outbreak in the town of Juba, Southern Sudan. This report summarizes the results of that investigation, which found that 3,157 persons were diagnosed with suspected cholera during January–June 2007, with 74 deaths resulting from the disease. An environmental investigation revealed suboptimal hygiene practices and a lack of water and sanitation infrastructure in Juba. A case-control study indicated that persons less likely to have cholera were more likely to have consumed hot meals containing meat during the outbreak. Contaminated food or water were not identified as possible sources of the cholera outbreak in Juba. However, this might be attributed to limitations of the study, including small sample size. Cholera can reach epidemic proportions if adequate control measures are not implemented early. Mass media campaigns are important for current and new residents in Juba to understand the importance of proper food handling, clean water, and optimal hygiene practices to prevent the spread of cholera.

After the civil war with North Sudan ended in 2005, displaced residents began returning to Juba. Juba is a major urban area in Central Equatoria State and is considered the unofficial capital of Southern Sudan. Housing in Juba for returning residents consisted of informal and formal settlements that included old brick homes, tent camps, and mud thatch houses. The major water sources were borehole well pumps, shallow watering holes, the Nile River, and tanker trucks. Latrines and indoor plumbing were lacking; as a result, some residents used open fields for defecation. Juba had one large open-air marketplace, in which persons could shop for food items, and very few restaurants. In February 2006, a large cholera outbreak began in Juba, resulting in 6,329 suspected infections as of June 2006, with sporadic cases continuing throughout the year.

## **Epidemiologic Investigation**

CDC's Coordinating Office for Global Health received a request for technical assistance from SS-FELTP in March 2007 to investigate a second large cholera outbreak in Juba. Investigators arrived at the end of April 2007, after the outbreak had peaked (weeks 10–11) (Figure) and after information about cholera prevention had been communicated to Juba residents. At the time of the investigation, Southern Sudan's Ministry of Health (MOH) was conducting a cholera prevention campaign that included radio prevention messages and community education forums. MOH defined a suspected cholera case as illness in a person of any age with acute watery diarrhea




FIGURE. Number of suspected cholera cases,\* by week of illness onset, and number of cholera deaths — Juba, Southern Sudan, 2007

\* Defined as illness in a person of any age with acute watery diarrhea.
 \* World Health Organization epidemiologic week.

during the 2007 outbreak. Contaminated water and food were hypothesized to be the main sources of cholera in Juba based on previous cholera studies conducted in Africa (1,2) and the lack of sanitation infrastructure observed in Juba. Potential risk factors for cholera were identified after discussions with persons living in Juba and health officials about possible routes of transmission. A review of the weekly surveillance records kept jointly by the World Health Organization (WHO) Juba office and MOH identified 3,157 persons with diagnoses of suspected cholera (case fatality rate: 2%) during January–June 2007 in Juba. The outbreak peaked in March and ended in June 2007. However, isolated cases continued for the remainder of 2007. Information on the number of persons infected with cholera was obtained from the Juba Teaching Hospital (JTH), cholera treatment centers coordinated by Medecins Sans Frontiers (MSF), and other local hospitals and clinics. A review of records from JTH revealed that information on sex, age, and symptoms was incomplete in the hospital admissions logbook.

## **Environmental Investigation**

Latrines, chlorine for treating water, and soap were lacking in Juba. Residents collected water from borehole pump wells using jerry cans (large plastic containers with small openings), the Nile River, and tanker trucks selling untreated Nile River water. Upon initial inspection, investigators observed an open defecation field near the Nile River, pit latrines built uphill from nearby borehole wells, and several wells closed because of contamination.

# **Case-Control Study**

A prospective matched case-control study was conducted during May 24-June 5 by SS-FELTP trainees and CDC investigators. A questionnaire was developed that included demographic characteristics, symptoms, potential exposures (e.g., related to food, water, personal hygiene, and sanitation), large gatherings (e.g., funerals and weddings), and knowledge of cholera prevention. Case-patients were identified upon admission to the infectious disease ward at JTH. For the purposes of the study, a case was defined as illness in a person of any age with acute watery diarrhea (with or without vomiting) in the 4 days before arriving at JTH. Selection of case-patients was consecutive. All persons admitted to JTH during May 24-June 5 who met the case definition were included in the study. Two case-patients died before they could be enrolled in the study and thus were excluded. Among those households with more than one case-patient, only the first ill person was enrolled in the study; secondary cases were excluded. Interviewers

traveled to each case-patient's place of residence and matched each case-patient to two community controls by age (within 5 years), sex, and neighborhood. Selected control residences were chosen randomly and could not be residences that were adjacent to the case-patient's residence. Persons living next to the case-patients' residences might have been more likely to also be infected with cholera because many of the home communes observed belonged to the same family, and members shared meals, latrines (if existing), and courtyards. Controls and their household members had no history of diarrhea since January 2007. Case-patients were interviewed in the hospital, and controls were interviewed in their residences. Information was collected on 42 cases and 81 controls. Both bivariate (chi-square) and multivariable (conditional logistic regression) analyses were performed. The multivariable analysis included all variables that were significant ( $p \le 0.05$ ) in the bivariate analysis. Stool specimens gathered by rectal swabs from 10 case-patients with suspected cholera who had not received antimicrobial treatment by a certified laboratory technologist were stored in Cary-Blair medium and shipped to the Kenya Medical Research Institute (KEMRI) laboratory in Nairobi, Kenya. Because of limited resources, only 10 specimens were shipped to KEMRI.

The median age of both case-patients and controls was 30 years (range: 3–60 years); 2% of case-patients and 1% of controls were aged <5 years. Approximately half (52%) of the case-patients entered the hospital within 1 day of becoming ill (Table 1). Other symptoms included vomiting, fever, and leg cramps. One third of the case-patients were reported as being severely dehydrated based on the nursing notes in the medical chart. Treatment consisted of oral fluids, tetracycline, doxycycline, and intravenous fluids and varied among case-patients. The majority of case-patients received intravenous fluids, but not all received oral fluids, tetracycline, or doxycycline.

The unadjusted matched analysis (Table 2) indicated that persons who 1) self-identified as visitors to Juba (matched odds ratio [mOR] = 5.6; 2) had lived less than 1 year in Juba (mOR = 4.6); and 3) chose a water source close to their place of residence (i.e.,  $\leq 20$  meters [mOR = 3.2]) were at greater odds of having cholera, all significant associations at  $p \le 0.05$ . Using tanker trucks drawing water from the Nile River as the main source of drinking water was not significantly associated with cholera. A significant association was observed for persons who did not treat their water (when compared with those who used chlorine treatment) were found to be at less risk for cholera (mOR = 0.2). No significant associations were observed between cholera and hygiene-related factors (i.e., using soap to wash hands before eating or after defecation, and having soap present in the house) or eating leftover foods. Consuming a meal with fish served hot in the 3 days before

TABLE 1. Clinical characteristics of 42 cholera cases* — Juba,
Southern Sudan, 2007

Characteristic	No.	(%)
Age (yrs) (median: 30)		
<5	1	(2)
5–14	5	(12)
15–25	6	(14)
26–44	20	(47)
>45	10	(24)
Sex		~ /
Male	22	(52)
Female	20	(48)
No. of days ill before hospital admission		( <i>'</i>
1	22	(52)
2	14	(33)
3	5	(12)
4	1	(2)
Watery diarrhea <sup>†</sup>		
Yes	42	(100)
No	0	
Vomiting <sup>†</sup>		
Yes	39	(93)
No	3	(7)
Leg cramps <sup>†</sup>		
Yes	15	(36)
No	27	(64)
Fever <sup>†</sup>		( )
Yes	42	(100)
No	0	
Dehydration level <sup>†</sup>		
None	5	(12)
Some	23	(55)
Severe	14	(33)
Oral fluids <sup>†</sup>		
Yes	14	(33)
No	28	(67)
Intravenous fluids <sup>†</sup>		
Yes	39	(93)
No	3	(7)
Tetracycline <sup>†</sup>		
Yes	2	(5)
No	40	(95)
Doxycycline <sup>†</sup>		
Yes	28	(67)
No	14	(33)

\* A case was defined as illness in a person of any age with acute watery diarrhea (with or without vomiting) in the 4 days before arriving at Juba Teaching Hospital.

<sup>†</sup>Obtained from case-patient charts at Juba Teaching Hospital.

becoming ill (case-patients) and before being interviewed (controls), was significantly protective for cholera (mOR = 0.3). A similar significant protective association was found for hot meals containing meat (mOR = 0.2). No significant associations with other local food items or attendance at large gatherings (e.g., funerals or weddings) were identified. After the significant variables from the bivariate analysis were included in a multivariable analysis, only consuming at least one hot meal containing meat in the 3 days before becoming ill (case-patients) or before being interviewed (controls) (adjusted mOR = 0.3 [95% confidence interval = 0.1–0.9], p = 0.03) was associated with a lowered risk for cholera.

	Cas	ses*	Con	trols	_ Matched		
Exposure	No.	(%)	No.	(%)	odds ratio	(95% Cl†)	p value§
Nonresident of Juba vs. resident (referent)	15/41	(36.6)	11/81	(13.6)	5.6	(1.6–19.6)	0.001
<1 yr in Juba vs. ≥1 yr in Juba (referent)	17/42	(40.5)	17/81	(21.0)	4.6	(1.4–14.8)	0.006
Drinking water source ≤20 m from residence vs. >20 m away (referent)	28/41	(68.3)	37/80	(46.3)	3.2	(1.2–8.4)	0.006
Drinking water from tanker truck vs. other water sources (referent)	6/35	(17.1)	9/66	(13.6)	1.8	(0.5–6.8)	0.243
Drinking untreated water vs. chlorinated water (referent)	28/40	(70.0)	71/79	(89.9)	0.2	(0.1–0.7)	0.007
Consumed a meal with hot fish vs. meal without hot fish (referent)	19/42	(45.2)	53/81	(65.4)	0.3	(0.1–0.8)	0.006
Consumed a meal with hot meat vs. meal without hot meat (referent)	20/42	(47.6)	66/81	(81.5)	0.2	(0.1–0.5)	0.001
Defecating in an open field vs. not defecating in open field (referent)	12/42	(28.6)	15/81	(18.5)	2.5	(0.8–7.6)	0.070
Not washing hands post defecation with soap vs. washing hands (referent)	24/42	(57.1)	54/81	(66.7)	1.7	(0.7–3.9)	0.151
Not washing hands before eating with soap vs. washing hands (referent)	15/42	(35.7)	34/81	(42.0)	1.3	(0.6–2.9)	0.343
Attended large gathering vs. did not attend one (referent)	9	(21.4)	9	(11.4)	2.2	(0.8–6.7)	0.100
Eat or store leftover food vs. did not eat or store (referent)	25	(59.5)	47	(58.0)	1.0	(0.4–2.5)	0.562
Soap not present in house vs. soap present in the house (referent)	11	(32.4)	27	(33.3)	1.0	(0.3–2.9)	0.600

\* A case was defined as illness in a person of any age with acute watery diarrhea (with or without vomiting) in the 4 days before arriving at Juba Teaching Hospital.

<sup>†</sup> Confidence interval.

§ Significant at  $p \le 0.05$ .

# Laboratory Results

Six of the 10 rectal swabs collected from the case-patients in the case-control study before antimicrobial treatment was started yielded *Vibrio cholerae* biotype El Tor, serogroup O1, serotype Inaba. This type was resistant to sulfatrimethoprim, nalidixic acid, sulfisoxazole, streptomycin, and furazolidone.

## **Control Measures**

The cholera outbreak in Juba ended in June 2007. At the time of the investigation, MOH established a working group with key stakeholders (the United Nations Children's Fund, the United Nations Office for Humanitarian Affairs, and WHO) and other international nongovernmental organizations to develop a strategy for cholera prevention and preparedness for Southern Sudan. The following strategies were implemented for the 2007 outbreak and any future outbreaks: 1) community health education, with emphasis on improved hygiene practices and sanitation; 2) establishment of food safety regulations for the local market; 3) expansion of the municipal water supply; 4) establishment of proper city waste disposal systems and house pit latrines; 5) banning of defecation in the three main streams in Juba; 6) a shift from informal to formal planned

settlements for houses; and 7) supervision of water treatment with chlorine at collection points along the Nile River.

**Reported by:** L Kur, MS, C Mounir, MD, J Lagu, MD, M Muita, MD, Southern Sudan Field Epidemiology and Laboratory Training Program; J Rumunu, MD, Ministry of Health, Government of Southern Sudan. B Ochieng, Kenya Medical Research Institute, Nairobi, Kenya. A Weathers, MPP, P Nsubuga, MD, E Maes, PhD, Div of Global Public Health Capacity Development, Coordinating Office for Global Health; I Rolle, PhD, EIS Officer, CDC.

**Editorial Note:** Cholera outbreaks continue to occur throughout Africa, despite advances in cholera surveillance, treatment, and prevention. The main contributors to cholera outbreaks worldwide include a lack of clean water, inadequate sanitation, and suboptimal food-handling practices (5). Cholera is a major public health concern because it induces acute severe diarrhea and can result in death if oral rehydration is not administered quickly (1). Once a cholera outbreak occurs, simple interventions can prevent infection: 1) washing hands with soap before eating, cooking, and after defecation; 2) eating cooked food served hot; and 3) drinking water treated by a recommended method (e.g., boiling, chlorination, or solar disinfection through UV+ heat) (5).

This investigation of cholera in Juba did not implicate a single source of water or food, which are common modes of cholera transmission. The unadjusted matched analysis indicated that the following were risk factors for cholera: 1) using a water source close to the place of residence (i.e.,  $\leq 20$  meters); 2) being a visitor to Juba; and 3) living less than 1 year in Juba. Persons consuming a meal with hot meat or hot fish were less likely to have cholera. Surprisingly, persons who did not treat their water also appeared to have a lower risk for cholera. Persons using untreated water might have been previously exposed to cholera and therefore might have developed some immunity. Moreover, among persons with cholera who treated their water, poor techniques for treating water with chlorine might have resulted in exposure to cholera. This is especially likely if those persons who used chlorine were more likely to have used visibly turbid water from the Nile River that was imperfectly disinfected by chlorine.

Despite these findings, the majority of the associations observed became insignificant in the multivariable analysis, which indicated that the initial results were artifacts or were attributed to limitations of the study. Only eating a hot meal containing meat in the 3 days before becoming ill (casepatients) or being interviewed (controls) remained significantly protective (p = 0.03) in the multivariable analysis when all the significant variables from the bivariate analysis were included. Knowledge of proper food handling and the importance of heating foods thoroughly before eating might have helped prevent the transmission of cholera in this population, as suggested by the lower odds of cholera by those persons eating at least one hot meal with meat. Cholera can grow in food kept at room temperature (5). Food was routinely cooked outside using makeshift stoves, and cold storage of food was limited because of a lack of electricity. Previous studies of cholera outbreaks have implicated the consumption of cold foods (e.g., seafood and raw vegetables) as risk factors for cholera and recommended that food be cooked and eaten hot (6, 7). Treatment of the case-patients consisted of the recommended WHO treatment of rehydration using oral rehydration and intravenous therapy. Approximately half of the case-patients received antibiotics, which WHO indicates should only be administered in severe cases (5). Only 14 case-patients were classified as having severe dehydration.

The findings in this report are subject to at least three limitations. First, the data collected in the case-control study (e.g., information related to the main source of drinking water and water treatment supplies) were self-reported. In addition, widespread exposure to health messages might have increased reports of risk-reducing behavior because of social desirability bias. The investigation team arrived after the outbreak had peaked, and the health messages had been in operation for at least 1 month before the team's arrival. Second, misclassification bias might have occurred because some of the controls might have developed immunity to cholera, and laboratory tests revealed that, of the 10 case-patients tested, only six were found to have cholera. Controls were not tested for cholera. As a result, some of the cases might not have been actual cases, and some of the controls might have been cases. Finally, the sample size for the case-control study was small and therefore might have limited significant associations for risk factors with p-values  $\leq 0.05$ .

In developing countries such as Southern Sudan or those recovering from war, returning residents might be at greater risk for diseases such as cholera. Cholera prevention strategies recommended by WHO and MSF that could be used for countries recovering from war include 1) encouraging proper food-handling techniques, including eating heated food; 2) intensifying surveillance to detect cases early; 3) building proper pit latrines; 4) cleaning defecation fields; 5) providing soap and chlorine free of charge or at a reduced cost; and 6) implementing appropriate water and sanitation policies (5,8).

#### Acknowledgments

This report is based, in part, on contributions by A Taban, O Jackson, E Kosti, J Benjamin, L Okeny, C Olur, B Samuel, Ministry of Health, Government of Southern Sudan; S Dada, World Health Organization, Juba Office, Southern Sudan; and E Mintz, MD, Div of Bacterial, Foodborne, and Mycotic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases, and T Handzel, PhD, Div of Emergency and Environmental Health Svcs, National Center for Environmental Health, CDC.

#### References

- 1. Sack DA, Sack RB, Balakrish G, Siddique AK. Cholera. Lancet 2004;363:223-33.
- Gaffga NH, Tauxe RV, Mintz ED. Cholera: a new homeland in Africa? Am J Trop Med Hyg 2007;77:705–13.
- 3. Sudanese peace treaty signed. Foreign Policy Bull 2006;16:100-33.
- Alwan A. Resource mobilization for health action in crises. Sudan. Geneva, Switzerland: World Health Organization; 2006. Available at http://www. who.int/hac/donorinfo/cap/Sudan\_Workplan\_Dec06.pdf.
- Global Task Force on Cholera Control. Cholera outbreak: assessing the outbreak response and improving preparedness. Geneva, Switzerland: World Health Organization; 2004. Available at http://www.who.int/ cholera/publications/cholera\_outbreak/en/print.html.
- CDC. Cholera epidemic associated with raw vegetables—Lusaka, Zambia, 2003–2004. MMWR 2004;53:783–6.
- Quick RE, Thompson BL, Zuniga A, et al. Epidemic cholera in rural El Salvador: risk factors in a region covered by a cholera prevention campaign. Epidemiol Infect 1995;114:249–55.
- Medecins Sans Frontiers. Refugee health. An approach to emergency situations. London, England: MacMillan; 1997. Available at http://www. refbooks.msf.org/msf\_docs/en/refugee\_health/rh1.pdf.

### Notice to Readers


# Abbreviations for Vaccines in Immunization Schedules: Advisory Committee on Immunization Practices

Each year, the Advisory Committee on Immunization Practices (ACIP) publishes immunization schedules that summarize recommendations for currently licensed vaccines for children aged 18 years and younger, and for adults (*1,2*). In February 2009, ACIP approved a listing of standardized vaccine abbreviations for use in these immunization schedules.

The table of standardized vaccine abbreviations was developed by staff members at CDC; ACIP members and workgroups; editors of *Epidemiology and Prevention of Vaccine-Preventable Diseases* (*3*); and others. These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP recommendations. The standardized vaccine abbreviations are available at http://www.cdc.gov/vaccines/recs/acip/ vac-abbrev.htm.

#### References

- CDC. Recommended immunization schedules for persons aged 0 through 18 years—United States, 2009. MMWR 2008;57(51&52).
- 2. CDC. Recommended adult immunization schedule—United States, 2009. MMWR 2009;57(53).
- 3. CDC. Epidemiology and prevention of vaccine-preventable diseases. Atkinson W, Hamborsky J, McIntyre L, Wolfe S, eds. 10th ed. 2nd printing. Washington, DC: Public Health Foundation; 2008.



In 2006, the United States devoted 15.3% of its GDP to health-care spending (i.e., health goods and services plus health-care infrastructure). Seven other countries devoted ≥10% of their GDP to health-care spending: Switzerland, France, Germany, Belgium, Portugal, Austria, and Canada. Five countries devoted <7% of their GDP to health-care spending: Czech Republic, Mexico, Korea, Poland, and Turkey.

**SOURCE:** Organisation for Economic Co-operation and Development. OECD health data 2008: statistics and indicators for 30 countries. Paris, France: Organisation for Economic Co-operation and Development; 2008. Available at http:// www.oecd.org/health/healthdata.

TABLE I. Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending April 4, 2009 (13th week)\*


	Current	Cum	5-year weekly	Total cases reported for previous years					States reporting cases
Disease	week	2009	average <sup>†</sup>	2008	2007	2006	2005	2004	during current week (No.)
Anthrax	_	_	_		1	1	_		
Botulism:									
foodborne	—	5	0	17	32	20	19	16	
infant	_	12	1	102	85	97	85	87	
other (wound and unspecified)		7	0	19	27	48	31	30	<b>21</b> (1)
Brucellosis	1	13	2	81	131	121	120	114	CA (1)
Chancroid	2	13	1	29	23	33	17	30	WI (1), TX (1)
Cholera	-	1	0	3	7	9	8	6	
Cyclosporiasis <sup>§</sup> Diphtheria	1	23	1	135	93	137	543	160	NY (1)
Domestic arboviral diseases <sup>§</sup> , <sup>¶</sup> :	_	_	_	_	_	_	_	_	
California serogroup	_	_	0	49	55	67	80	112	
eastern equine	_	_	_	3	4	8	21	6	
Powassan	_	_	_	2	7	1	1	1	
St. Louis	_	_	0	10	9	10	13	12	
western equine	_	_	_	_	_	_	_	_	
Ehrlichiosis/Anaplasmosis <sup>§</sup> ,**:									
Ehrlichia chaffeensis	3	32	2	875	828	578	506	338	NY (1), TN (2)
Ehrlichia ewingii	_		—	8	_	_	_		
Anaplasma phagocytophilum	2	11	2	583	834	646	786	537	NY (1), NC (1)
undetermined	1	5	1	65	337	231	112	59	TN (1)
Haemophilus influenzae, <sup>††</sup>									
invasive disease (age <5 yrs):		0	0	20	00	00	0	10	
serotype b	1	9 56	0 4	30 192	22 199	29 175	125	19 135	OK(1)
nonserotype b unknown serotype	1	49	4	192	180	175	135 217	177	OK (1) FL (1)
Hansen disease <sup>§</sup>	_	14	2	79	100	66	87	105	
Hantavirus pulmonary syndrome§	_	1	0	18	32	40	26	24	
Hemolytic uremic syndrome, postdiarrheal§	1	28	3	267	292	288	221	200	CT (1)
Hepatitis C viral, acute	7	170	14	863	845	766	652	720	NY (1), MO (1), KS (1), KY (1), TN (1), WA (2)
HIV infection, pediatric (age <13 years)§§	_	_	3	_	_	_	380	436	
Influenza-associated pediatric mortality <sup>§</sup> , <sup>¶¶</sup>	2	46	2	88	77	43	45	_	IL (1), VA (1)
Listeriosis	7	115	10	730	808	884	896	753	PA (1), ID (1), WA (3), CA (2)
Measles***	3	10	2	138	43	55	66	37	PA (3)
Meningococcal disease, invasive <sup>†††</sup> :	•		0		005	010	007		<b>DA</b> (4) <b>DO</b> (4)
A, C, Y, and W-135	2	75	8	328	325	318	297	_	PA (1), CO (1)
serogroup B	2	41 6	3 1	180 30	167 35	193 32	156 27	_	MN (1), SC (1)
other serogroup unknown serogroup	7	126	19	606	550	651	765	_	CT (1), VA (1), FL (2), KY (1), TN (1), CA (1)
Mumps	3	77	67	437		6,584	314	258	PA (1), AZ (2)
Novel influenza A virus infections	_	1		2	4	0,00 I N	N	N	
Plague	_	_	_	1	7	17	8	3	
Poliomyelitis, paralytic	_	_	_	_	_	_	1	_	
Polio virus infection, nonparalytic§	_	_	—	—	_	N	N	N	
Psittacosis§	—	5	0	11	12	21	16	12	
Q fever total <sup>§</sup> , <sup>§§§</sup> :	—	11	2	100	171	169	136	70	
acute	_	8	1	89	_	_	_		
chronic Debies human	_	3	_	11					
Rabies, human Rubella <sup>1111</sup>	_	_	0	1	1	3	2 11	7 10	
Rubella	_	1	0	18	12	11 1	1	10	
SARS-CoV <sup>§</sup> ,****	_	_	_	_	_	_		_	
Smallpox <sup>§</sup>	_	_	_	_	_	_	_	_	
Streptococcal toxic-shock syndrome§	5	47	4	146	132	125	129	132	NY (3), MN (2)
Syphilis, congenital (age <1 yr)		32	7	348	430	349	329	353	
Tetanus	_	3	0	19	28	41	27	34	
Toxic-shock syndrome (staphylococcal)§	_	17	2	73	92	101	90	95	
Trichinellosis	—	7	0	37	5	15	16	5	
Tularemia		4	0	118	137	95	154	134	
Typhoid fever	3	87	6	433	434	353	324	322	FL (1), CA (2)
Vancomycin-intermediate Staphylococcus aureus		14	0	46	37	6	2	_	OH (1), MO (1), FL (1)
Vancomycin-resistant <i>Staphylococcus aureus</i> <sup>§</sup>	_		0	400	2	1	3	1	
Vibriosis (noncholera Vibrio species infections)§	2	35	2	492	549	Ν	N	Ν	FL (1), CA (1)
Yellow fever	_	_					_		

See Table I footnotes on next page.

# TABLE I. (*Continued*) Provisional cases of infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) — United States, week ending April 4, 2009 (13th week)\*

- -: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts.
- \* Incidence data for reporting year 2008 and 2009 are provisional, whereas data for 2004, 2005, 2006, and 2007 are finalized.
- <sup>†</sup> Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. Additional information is available at http://www.cdc.gov/epo/dphsi/phs/files/5yearweeklyaverage.pdf.
- S Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
- <sup>1</sup> Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II.
- \*\* The names of the reporting categories changed in 2008 as a result of revisions to the case definitions. Cases reported prior to 2008 were reported in the categories: Ehrlichiosis, human monocytic (analogous to *E. chaffeensis*); Ehrlichiosis, human granulocytic (analogous to *Anaplasma phagocytophilum*), and Ehrlichiosis, unspecified, or other agent (which included cases unable to be clearly placed in other categories, as well as possible cases of *E. ewingii*).
- <sup>††</sup> Data for *H. influenzae* (all ages, all serotypes) are available in Table II.
- <sup>§§</sup> Updated monthly from reports to the Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Implementation of HIV reporting influences the number of cases reported. Updates of pediatric HIV data have been temporarily suspended until upgrading of the national HIV/AIDS surveillance data management system is completed. Data for HIV/AIDS, when available, are displayed in Table IV, which appears quarterly.
- <sup>11</sup> Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Forty-five influenza-associated pediatric deaths occurring during the 2008-09 influenza season have been reported.
- \*\*\* The three measles cases reported for the current week were imported.
- <sup>+++</sup> Data for meningococcal disease (all serogroups) are available in Table II. <sup>§§§</sup> In 2008, Q fever acute and chronic reporting categories were recognized as a result of revisions to the Q fever case definition. Prior to that time, case counts were not
- differentiated with respect to acute and chronic Q fever cases.
- 1111 No rubella cases were reported for the current week.
- \*\*\*\* Updated weekly from reports to the Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases.

# FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals April 4, 2009, with historical data



\* Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

Notifiable Disease Data Team and 122 Cities Mortality Data TeamPatsy A. HallDeborah A. AdamsRosaline DharaWillie J. AndersonMichael S. WodajoLenee BlantonPearl C. Sharp

(13th week)*			Chlamydi	at			Cocc	idiodomy			Cryptosporidiosis					
		Previ	<u> </u>	a.			Prev		0315			Prev		0515		
	Current	E0		Cum	Cum	Current	52 w		Cum	Cum	Current	52 w		Cum	Cum	
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008	
United States	13,812 768	21,893 732	25,375 1.656	253,702 9.824	277,152 8.647	87	126 0	343 0	1,860	1,696 1	44 3	107 5	475 23	867 55	898 91	
New England Connecticut	223	226	1,306	2,790	1,854	Ν	0	0	N	Ň		0	7	7	41	
Maine <sup>§</sup> Massachusetts	44 441	48 323	72 954	667 5,135	679 4,513	N N	0	0 0	N N	N N	_	1 2	6 13	4 27	2 23	
New Hampshire	5	36	63	256 693	540 769	_	0 0	0 0	_	1	_	1 0	4	7	11	
Rhode Island <sup>§</sup> Vermont <sup>§</sup>	33 22	52 21	208 53	283	292	N	0	0	N	N	3	1	3 7	9	2 12	
Mid. Atlantic New Jersey	3,293	2,833 397	6,461 755	36,635 3,671	34,215 5,862	N	0 0	0 0	N	N	8	13 0	34 2	107	121 10	
New York (Úpstate)	875	560	4,229	7,512	6,052	N	0	0	N	N	2	4	17	35	27	
New York City Pennsylvania	2,060 358	1,105 784	3,381 1,074	15,893 9,559	11,466 10,835	N N	0 0	0 0	N N	N N	6	1 5	8 15	18 54	25 59	
E.N. Central	1,614	3,343	4,294	34,087	47,525	1	1	3	8	13	9	26	125	191	192	
Illinois Indiana	343 540	1,065 378	1,315 713	9,268 5,238	14,264 5,142	N N	0 0	0 0	N N	N N	2	2 3	13 13	14 20	21 15	
Michigan Ohio	522 45	842 797	1,225 1,346	11,475 4,406	11,213 11,575	1	0	3 2	2 6	10 3	1	5 6	13 59	46 58	44 54	
Wisconsin	164	293	439	3,700	5,331	Ň	0	Ō	Ň	Ň	6	9	46	53	58	
W.N. Central lowa	829 178	1,323 182	1,550 256	15,843 2,445	16,547 2,213	1 N	0 0	1 0	1 N	N	6 2	16 4	68 30	106 22	119 33	
Kansas Minnesota	166	185 266	401 310	2,430 2,293	2,181 3,760	N	0 0	0 0	N	N	3	1 4	8 14	17 16	12 31	
Missouri	357	494	577	6,571	5,977	1	0	1	1		1	3	13	24	15	
Nebraska <sup>§</sup> North Dakota	76	101 28	254 60	1,187 156	1,242 495	N N	0 0	0 0	N N	N N	_	2 0	8 2	14 1	15 1	
South Dakota	52	57	85	761	679	Ν	0	0	N	N		1	9	12	12	
S. Atlantic Delaware	2,207 61	3,913 70	6,326 163	42,770 1,260	47,994 903	_	0 0	1 1	4 1	_2	11	18 0	47 1	194	156 4	
District of Columbia Florida	1,165	128 1,397	229 1,571	1,751 18,386	1,687 16,739	N	0 0	0 0	N	N	1	0 8	2 35	64	2 76	
Georgia	2	617	1,274	3,074	8,716	Ν	0	0	N	N	7	5	13	85	47	
Maryland <sup>§</sup> North Carolina	317	441 0	692 460	5,363	5,332 2,352	N	0 0	1 0	3 N	2 N	2	1 0	4 16	7 26	2 9	
South Carolina <sup>§</sup> Virginia <sup>§</sup>	662	527 606	3,038 885	6,259 5,779	4,495 6,872	N N	0 0	0 0	N N	N N	1	1	4 4	4 6	6 6	
West Virginia	—	61	102	898	898	N	0	Ō	N	N	—	Ó	3	2	4	
E.S. Central Alabama <sup>§</sup>	1,403	1,667 467	2,150 553	21,878 4,539	20,072 6,373	N	0 0	0 0	N	N	_	3 1	9 6	25 5	25 13	
Kentucky	179	253 413	380 841	3,149	2,550 4,328	N	0 0	0 0	N N	N N	_	0	4 2	6 4	4	
Mississippi Tennessee <sup>§</sup>	584 640	546	798	6,456 7,734	6,821	N	0	0	N	N	_	1	5	10	5	
W.S. Central Arkansas <sup>§</sup>	1,598 204	2,831 275	3,691 392	34,751 3,824	36,254 3,715	N	0 0	1 0	N	1 N	_	8 1	256 7	37 3	42 2	
Louisiana	_	425	822	3,782	4,469	_	0	1	_	1	_	1	5	5	8	
Oklahoma Texas§	80 1,314	188 1,931	407 2,496	1,484 25,661	3,067 25,003	N N	0 0	0 0	N N	N N	_	1 5	16 250	10 19	11 21	
<b>Mountain</b> Arizona	657 274	1,259 475	1,984 645	13,896 4,836	18,373 5,955	60 58	89 87	181 179	1,289 1,264	1,156 1,121	3 1	8 1	39 9	55 7	81 11	
Colorado		159	588	1,446	4,426	N	0	0	Ń	Ń	_	1	12	17	18	
Idaho <sup>§</sup> Montana <sup>§</sup>	17	67 59	314 87	833 726	1,062 765	N N	0 0	0 0	N N	N N	_2	1	5 3	8 3	14 9	
Nevada <sup>§</sup> New Mexico <sup>§</sup>	187 139	175 150	415 455	2,701 1,985	2,543 1,811	_2	1 0	7 2	20 1	16 11	_	0 2	4 24	5 9	3 13	
Utah	2	101	252	825	1,511	—	0	1	4	8	_	0	6	1	8	
Wyoming <sup>§</sup> Pacific	38 1,443	33 3.665	97 4 461	544	300 47,525	 25	0 37	1 172	558	 523	4	0 8	2 30	5 97	5 71	
Alaska	47	3,665 88	4,461 200	44,018 1,068	1,160	N	0	0	N	N	_	0	1	1	1	
California Hawaii	1,353 43	2,874 112	3,308 248	35,668 1,293	36,713 1,385	25 N	37 0	172 0	558 N	523 N	1	5 0	14 1	54	46 1	
Oregon <sup>§</sup> Washington	_	186 375	631 502	2,373 3,616	2,630 5,637	N N	0	0	N N	N N	3	1	5 17	34 8	14 9	
American Samoa C.N.M.I.	_	0	14		37	N	0	0	N	N	N	0	0	N	<u>N</u>	
Guam	104	5	24	1.070	25	_	0	0	_	_	_	0	0			
Puerto Rico U.S. Virgin Islands	134	146 10	333 22	1,979	1,299 188	N 	0 0	0 0	N	N 	N	0 0	0 0	N 	N	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting year 2008 and 2009 are provisional. Data for HIV/AIDS, AIDS, and TB, when available, are displayed in Table IV, which appears quarterly. † Chlamydia refers to genital infections caused by *Chlamydia trachomatis*. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

			Giardiasi	s				Gonorrhe	a	Haemophilus influenzae, invasive All ages, all serotypes <sup>†</sup>					
	Previous 52 weeks						vious veeks		_			/ious /eeks			
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008
United States	155	311	624	3,275	3,511	2,984	5,868	6,843	58,656	78,391	26	47	112	640	841
New England	7	28	65	265	330	89	101	301	1,238	1,151	1	3	17	39	43
Connecticut Maine <sup>§</sup>	7	6 3	14 12	53 49	74 29	34 4	51 2	275 7	545 34	386 23	1	0 0	11 2	10 5	1 4
Massachusetts	—	11	27	102	143	42	38	113	542	617	—	1	5	20	30
New Hampshire Rhode Island <sup>§</sup>	_	3 1	11 8	19 11	27 25	8	2 5	6 16	26 80	26 89	_	0 0	2 7	2 1	5
Vermont§	—	3	15	31	32	1	1	3	11	10	—	0	3	1	3
Mid. Atlantic New Jersev	34	59 0	108 14	578	668 117	548	607 89	1,077 146	7,086 745	7,639 1,497	3	9 1	23 5	120 10	144 29
New York (Upstate)	28	23	73	265	206	146	115	621	1,376	1,397	2	3	19	38	34
New York City Pennsylvania	4 2	16 15	30 46	167 146	181 164	345 57	205 201	584 267	2,840 2,125	1,943 2,802	1	1 4	6 10	13 59	25 56
E.N. Central	21	49	88	461	531	493	1,183	1,579	10,439	17,092	_	7	18	69	131
Illinois Indiana	N	11 0	32 7	62 N	138 N	122 159	364 146	480 254	2,670 1,724	4,769 2,112	_	2 1	7 13	20 10	44 25
Michigan		12	22	125	115	159	303	254 657	3,671	4,240	_	1	2	6	25 7
Ohio Wisconsin	14 7	17 9	31 20	187 87	195 83	16 52	267 79	531 141	1,335 1,039	4,414 1,557	_	2 0	6 2	30 3	45 10
W.N. Central	8	26	143	257	346	168	317	391	3.447	4,159	4	3	14	46	57
Iowa	_	6	18	60	61	22	28	53	327	386	_	0	1	_	1
Kansas Minnesota	2	3 0	11 106	28 2	25 115	42	44 55	83 78	617 379	525 858	4	0	4 10	6 11	4 11
Missouri	4	8	22	113	89	79	147	193	1,679	1,946	_	1	4	19	30
Nebraska <sup>ş</sup> North Dakota	2	4 0	10 4	34 3	34 8	17	27 2	50 7	344 6	350 33	_	0	2 3	7 3	7 4
South Dakota	—	2	11	17	14	8	8	20	95	61	—	0	0	_	—
S. Atlantic Delaware	43	60 1	108 3	836 5	546 11	622 4	1,279 17	1,875 35	11,973 214	17,082 316	13	12 0	24 2	201 1	234 2
District of Columbia	_	Ó	5	_	10	_	57	101	727	539	_	0	2	_	4
Florida Georgia	23 2	31 9	57 63	466 186	253 125	321 5	430 257	518 484	5,242 1.005	5,900 3,251	9 3	4	9 9	76 44	56 57
Maryland§	5	5	10	57	50	124	117	210	1,459	1,534	1	1	5	27	42
North Carolina South Carolina§	N 7	0 2	0 6	N 25	N 26	168	0 178	203 829	1,852	1,269 1,865	_	1	6 7	19 12	23 14
Virginia§	3	8	31	86	53	—	177	321	1,346	2,191	—	1	5	11	29
West Virginia E.S. Central	3	1 8	5 22	11 67	18 99		12	26 771	128	217	_	0 3	3 6	11	7
Alabama§	_	8 4	12	33	99 58	366	550 175	216	6,449 1,426	7,267 2,603	_	0	2	29 6	46 5
Kentucky	N N	0 0	0 0	N N	N N	47 164	88 140	153 253	898 1,984	970 1,672	_	0 0	3 1	_2	1 8
Mississippi Tennessee§		4	13	34	41	155	165	301	2,141	2,022	_	2	5	21	32
W.S. Central	4	8	21	62	56	406	949	1,300	9,840	12,719	2	2	17	27	30
Arkansas <sup>§</sup> Louisiana	1	2 2	8 10	17 27	23 20	63	84 161	167 317	1,110 1,260	1,217 2,306	1	0	2 1	3 4	2
Oklahoma	2	3	11	18	13	19	70	142	529	1,207	1	1	16	20	25
Texas <sup>§</sup> Mountain	N 8	0 27	0 62	N 221	N 302	324 92	605 196	728 339	6,941 1,575	7,989 2,837	3	0 5	1 11	77	3 122
Arizona	4	3	8	34	30	20	63	83	540	899	_	2	6	35	55
Colorado Idaho <sup>§</sup>	_	10 4	27 14	77 24	106 30	_	55 3	101 13	193 24	725 52	2	1	5 4	19 1	23 1
Montana§	1	2	9	23	19	3	2	6	22	24		Ō	1	1	1
Nevada <sup>§</sup> New Mexico <sup>§</sup>	1	1 1	8 8	9 10	29 29	36 32	34 23	129 48	503 229	665 309	1	0	2 2	7 6	6 16
Utah	_	7	18	32	49	—	6	19	47	149	—	0	2	8	20
Wyoming <sup>§</sup> Pacific	2 30	0 56	3 152	12 528	10 633	1 200	2 576	9 662	17 6,609	14 8,445	_	0 2	2 6	32	 34
Alaska	_	2	10	17	20	10	12	24	172	121	_	0	2	3	4
California Hawaii	22	35 0	59 4	387 2	464 7	184 6	475 12	577 21	5,561 132	6,918 144	_	0 0	3 2	5 9	11 4
Oregon <sup>§</sup> Washington	3 5	7 8	18 99	66 56	109 33		23 51	48 82	293 451	365 897	_	1 0	4 2	14 1	15
American Samoa C.N.M.I.	_	0	0			_	0	_1		_1	_	0	0	_	_
Guam	_	0	0			_	1	15		15	_	0	0	_	_
Puerto Rico	—	3	15	23	32	5	5	22	48	63	_	0	1	_	—

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Med \* Incidence data for reporting year 2008 and 2009 are provisional. † Data for *H. influenzae* (age <5 yrs for serotype b, nonserotype b, and unknown serotype) are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS). Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

·				Hepat	itis (viral,	acute), by	type†									
			Α					В			Legionellosis					
		Prev 52 w						vious veeks					vious veeks			
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	
United States	27	44	76	405	638	34	71	147	755	894	13	49	148	346	460	
New England	1	2	8	23	39	_	1	4	7	23	—	2	18	12	19	
Connecticut Maine <sup>§</sup>	_	0 0	4 5	7 1	5 3	_	0 0	2 2	3 3	9 4	_	1 0	5 2	5	3	
Massachusetts	_	1	3	11	23	_	0	2	_	7	_	1	7	5	6	
New Hampshire Rhode Island <sup>§</sup>	1	0	2 2	1 3	1 7	_	0 0	2 1	1	1	_	0 0	5 14	1	4 3	
Vermont§	_	Õ	1	_	_	_	Ő	1	_	1	_	Õ	1	1	3	
Mid. Atlantic New Jersev	3	5 1	10 3	49 5	87 20	2	7 1	15 5	53 3	132 52	_2	14 1	59 8	85 6	102 12	
New York (Upstate)	3	1	4	12	16	2	1	10	17	11	2	5	21	32	22	
New York City Pennsylvania	—	2 1	6 4	14 18	25 26	_	1 2	6 8	7 26	22 47	_	1 6	12 33	3 44	13 55	
E.N. Central	_	6	16	46	20 90	3	9	18	93	111	1	8	41	65	120	
Illinois	_	2	10	9	28	_	2	7	12	28	_	1	13	—	20	
Indiana Michigan	_	0 2	4 5	3 15	3 42	1	1 3	7 8	12 30	5 41	_	1 2	6 16	6 14	6 32	
Ohio	_	1	4	14	8	2	2	14	39	31	1	3	18	42	59	
Wisconsin W.N. Central	2	0 3	3 15	5 22	9 73	2	0 2	0 15	42	6 15		0 2	3 8	3 4	3 23	
lowa		1	7	—	29		0	3	42	6	_	0	2	2	23 5	
Kansas Minnesota	1	0	3 12	2 5	5 9	1	0 0	3 11	6	3	—	0	1 4	1	1 2	
Missouri	_	1	3	9	8	1	1	5	22	5	_	1	7	_	8	
Nebraska <sup>§</sup> North Dakota	1	0 0	5 1	6	21	—	0 0	3 1	7	1	—	0 0	3 1		6	
South Dakota	_	0	1	_	1	_	0	1	1	_	_	0	1		1	
S. Atlantic	12	7	16	109	81	18	18	34	271	228	8	9	22	88	86	
Delaware District of Columbia		0	1 0	U	1 U	U	0	2 0	8 U	7 U	_	0	2 2	_	1 3	
Florida	5	3	8	59	35	8	7	11	92	80	6	3	7	40	38	
Georgia Maryland <sup>§</sup>	1 1	1	4 4	15 13	12 11	1 1	3 2	8 5	34 27	35 25	1	1 2	5 10	17 14	9 18	
North Carolina	3	0	9	12	9	7	0	19	86	24	1	0	7	13	5	
South Carolina <sup>§</sup> Virginia <sup>§</sup>	2	0 1	3 6	5 5	2 8	1	1 2	4 10	3 12	22 20	_	0 1	2 5	4	2 7	
West Virginia	—	0	1	_	3	—	1	6	9	15	—	0	3	_	3	
E.S. Central Alabama <sup>§</sup>	_	1 0	9 2	8 1	8 1	_2	8 2	13 7	72 20	95 26	_	2 0	10 2	18 2	23 2	
Kentucky	_	0	3	1	3	1	2	7	17	26	_	1	4	8	13	
Mississippi Tennessee <sup>§</sup>	_	0	2 6	4 2	4	1	1 3	3 8	5 30	12 31	_	0 0	1 5	8	8	
W.S. Central	_	4	15	32	56	1	12	56	110	175	1	2	17	12	10	
Arkansas§	—	0	1	1	1	—	0	4	2	7	_	0	2	_	_	
Louisiana Oklahoma	_	0 0	2 5	2 1	3 3	1	1 2	4 10	9 24	23 15	_	0 0	2 6	1 1	1	
Texas§	—	4	11	28	49	—	8	45	75	130	1	1	16	10	9	
Mountain Arizona	6 6	3 1	12 11	31 17	53 18	_	3 1	11 5	30 12	39 17	_	1 0	8 2	21 8	26 7	
Colorado	_	Ó	2	4	11	_	0	3	6	5	_	0	2	1	3	
Idaho <sup>§</sup> Montana <sup>§</sup>	_	0	3 1	2	8	_	0 0	2 1	1	_	_	0	1 2	3	1 2	
Nevada§	_	0	3	4	2	_	1	3	6	11	—	0	2	5	3	
New Mexico <sup>§</sup> Utah	_	0	2 2	1 3	9 2	_	0 0	2 3	3 2	5 1	_	0 0	2 2	4	3 7	
Wyoming§	—	0	0	_	3	—	0	1	—	—	—	0	0	_	—	
Pacific Alaska	3	8 0	25 1	85 1	151 1	6	7 0	42 1	77 1	76 2	1	4 0	10 1	41 2	51	
California	1	7	25	70	120	4	5	28	61	54	_	3	8	32	42	
Hawaii Oregon <sup>§</sup>	_	0 0	2 2	1 6	3 12	1	0 1	1 3	1 7	3 9	_	0 0	1 2	1 3	2 4	
Washington	2	0	27	6 7	12	1	0	14	7	8	1	0	4	3	4	
American Samoa		0	0	—	—	_	0	0	—	_	Ν	0	0	Ν	Ν	
C.N.M.I. Guam	_		0	_	_	_		0	_	_	_		0	_	_	
Puerto Rico	—	0	4	5	7	—	0	5	1	13	_	0	0	_	_	
U.S. Virgin Islands	—	0	0	_			0	0			—	0	0		_	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting year 2008 and 2009 are provisional. † Data for acute hepatitis C, viral are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

		L	.yme disea	se				Malaria		Meningococcal disease, invasive <sup>†</sup> All serotypes					
			vious veeks				Prev 52 w						/ious /eeks		
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008
United States	95	488	1,675	1,413	1,904	13	23	47	210	168	11	19	41	248	402
New England	3	80	537	156	339	_	1	6	7	7	1	0	4	11	13
Connecticut Maine <sup>§</sup>	3	0 5	0 73	29	37	_	0 0	3 0	_	1	1	0 0	0 1	1	1
Massachusetts	_	38	362	46	232	_	0	4	6	4	_	0	3	6	11
New Hampshire Rhode Island <sup>§</sup>	_	17 0	143 5	55 5	62 1	_	0	2	_	1	_	0 0	1	1	_
Vermont§	_	4	41	21	7	_	0	1	1	_	_	0	1	1	_
/lid. Atlantic	54	254	1,299	692	996	3	4	14	41	37	1	2	6	22	43
New Jersey New York (Upstate)	 50	29 99	211	138 305	275	3	0 1	0 10	14	4	_	0 0	1	1 4	7
New York (Opstate)	50	99 4	1,247 36	305	111 40		3	10	21	27	_	0	2 2	4	14 5
Pennsylvania	4	97	519	249	570	—	1	3	6	6	1	1	4	14	17
.N. Central	_	11	147	26	64	1	3	7	26	33	_	3	8	41	66
Illinois Indiana	_	0 0	13 8	1	3	_	1 0	5 2	8 5	17 1	_	1	6 4	6 9	26 9
Vichigan	_	1	10	4	4	_	Ō	2	4	5	_	ŏ	3	7	11
Ohio	_	0 9	6	2 19	3	1	0	2	9	9	_	1	4 2	16	13
Wisconsin	7	9	129		54	_	1	3		1		0 1	2	3	7
<b>/.N. Central</b> Iowa		9	236 9	23 4	9 8	_	0	10 3	6 1	6	1	0	2	21 1	40 8
Kansas		0	4	2	1	—	0	2	1	_	_	0	2	5	1
Minnesota Missouri	7	5 0	226 1	16	_	_	0	8 3	1 3	1	1	0	4 2	5 8	15 11
Nebraska§	_	0	2	_	_	_	0	1	_	4	_	0	1	2	4
North Dakota South Dakota	_	0 0	10 1	1	_	_	0	0	_	_	_	0 0	1	_	1
. Atlantic	25	75	224	456	442	7	6	15	89	44	4	3	9	48	53
Delaware	25	12	36	430	107	_	0	15	1	44	4	0	9	40	- 55
District of Columbia	—	2	11		23	_	0	2				0	0		
Florida Georgia	_	2 0	10 6	12 13	8	2 1	1	7 5	25 15	14 10	2	1 0	4 2	24 6	19 5
Varyland§	7	29	162	250	249	3	1	7	27	16	_	0	3	1	4
North Carolina South Carolina <sup>§</sup>	6	0 0	5 2	14 3	2 4	1	0	7 1	13 1	2 1	1	0 0	3 2	9 3	3 10
Virginia <sup>§</sup>	11	15	61	76	45	_	1	3	6	1	1	0	2	4	11
West Virginia	—	1	11	9	4	_	0	1	1	—	—	0	1	1	1
.S. Central	1	1	5	4	1	_	0	2	5	2	2	0	6	8	21
Alabama <sup>§</sup> Kentucky	_	0 0	2 2	_	_	_	0	1	1	1 1	1	0 0	2 1	2	1 4
Mississippi	_	0	1	_	_	_	0	1	_	_		0	2	1	5
Tennessee§	1	0	3	4	1		0	2	4	_	1	0	3	5	11
<b>/.S. Central</b> Arkansas <sup>§</sup>	_	2 0	21 0	4	9	_	1	10 0	4	9	_	2 0	10 2	21 4	41 4
Louisiana	_	0	1	_	_	_	Ō	1	_	_	_	0	3	7	12
Oklahoma Toxoo <sup>§</sup>	_	0	1		_	—	0 1	2		1	_	0	3	2	6
Texas <sup>§</sup>	2	2 1	21 14	4 7	9 5	_	1 0	10 3	4 2	8 8	- 1	1	9 4	8 21	19 22
<b>ountain</b> Arizona	2	0	2	1	5	_	0	3		8	_	0	2	4	23 2
Colorado		0	1	1	1	—	0	1	1	3	1	0	2	7	5
daho <sup>§</sup> Vontana <sup>§</sup>	1 1	0 0	1 14	2 1	1	_	0	1 0	_	_	_	0 0	1	3 2	2 1
Nevada§	_	0	2	2	_	_	0	1	_	3	_	0	1	2	5
New Mexico <sup>§</sup> Utah	—	0 0	2 1	_	1	_	0 0	1	1	_	_	0 0	1	1	3 4
Wyoming <sup>§</sup>	_	0	1	_	_	_	0	0	_	_	_	0	1	1	4
acific	3	4	19	45	39	2	3	11	30	22	1	4	13	55	102
Alaska	_	0	2	1	—	_	0	2	1	—	_	0	2	2	—
California Hawaii	3 N	3 0	8 0	38 N	34 N	_2	2 0	8 1	20 1	17 1	1	2 0	8 1	27 1	84 1
Oregon <sup>§</sup>	_	1	3	6	5	_	0	2	4	3	_	1	6	19	9
Washington	—	0	12		_	—	0	7	4	1	—	0	5	6	8
merican Samoa .N.M.I.	N	0	0	N	N	_	0	0	_	_	_	0	0	—	_
iuam	_	0	0	_	_	_	0	2	_	_	_	0	0	_	_
Puerto Rico	Ν	0	0	N	Ν	—	0	1	1	—	_	0	1	—	2
J.S. Virgin Islands	N	0	0	N	Ν	_	0	0	_	_	—	0	0	_	_

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting year 2008 and 2009 are provisional. † Data for meningococcal disease, invasive caused by serogroups A, C, Y, and W-135; serogroup B; other serogroup; and unknown serogroup are available in Table I. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(13th week)*								<del></del>		Pocky Mountain spotted fover						
		Dro	Pertussis vious	;			Ra	bies, anin	nal	Rocky Mountain spotted fever Previous						
	Current		veeks	Cum	Cum	Current	52 w		Cum	Cum	Current		veeks	Cum	Cum	
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008	week	Med	Max	2009	2008	
United States	101	213	1,487	2,350	1,816	26	91	162	576	962	23	40	145	167	55	
New England Connecticut	_	16 0	35 4	129	263 22	8 4	8 3	21 17	65 26	69 37	_	0 0	2 0	1	1	
Maine <sup>†</sup>	_	1	7	26	12	4 3	1	5	11	8	_	0	1	1	_	
Massachusetts New Hampshire	_	13 1	30 4	84 10	203 8	_	0 1	0 8	5	7	_	0	1	_	1	
Rhode Island <sup>†</sup>	_	0	8	3	13	_	1	3	7	6	_	0	2	_	_	
Vermont <sup>†</sup>	_	0	2	6	5	1	1	6	16	11	_	0	0	_	_	
Mid. Atlantic New Jersey	5	18 1	52 6	184 17	200 14	8	31 0	67 0	92	270	_	1 0	30 2	3	9 2	
New York (Upstate)	3	6	41	40	58	8	10	20	72	73	_	0	29		—	
New York City Pennsylvania	2	0 9	20 34	17 110	29 99	_	0 21	2 52	20	5 192	_	0 0	2	3	4 3	
E.N. Central	2	36	174	528	458	_	3	29	7	2	_	1	15	3	1	
Illinois Indiana	_	12 2	45 96	119 32	41 12	_	1 0	21 2	_2	1	_	1 0	11 3	1	1	
Michigan	2	7	21	131	43	_	1	9	5		—	0	1	1	_	
Ohio Wisconsin	_	10 2	57 7	240 6	348 14	N	1 0	7 0	N	1 N	_	0 0	4	1	_	
W.N. Central	58	26	839	480	148	4	5	17	45	26	_	4	33	6	2	
lowa Kansas	4	4 2	21 12	34 37	26 18	2	0 1	5 9	26	3 7	_	0 0	2 0	_	_	
Minnesota	49	2	781	49	14	1	0 1	10	5	8	—	0	0	_		
Missouri Nebraska†	3 2	9 3	51 32	300 52	76 11	_	0	8 0	6	_	_	4 0	32 4	6	_2	
North Dakota South Dakota	_	0 0	18 10	2 6	3	1	0	9 2	3 5	3 5	_	0 0	0 1	_	_	
Souri Dakola S. Atlantic	6	20	71	316	152	2	25	2 78	290	509	21	16	71	143	26	
Delaware	_	0	3	4	1	_	0	0	_	_	—	0	5	1	1	
District of Columbia Florida	6	0 7	1 20	106	2 30	_	0	0 14	41	139	_	0	2 3	1	1	
Georgia	—	1	9	4	8	—	0	47	88	96	1	1	8	5	4	
Maryland <sup>†</sup> North Carolina	_	2 0	9 65	20 119	24 39	N	7 2	17 4	60 N	107 N	1 19	1 8	7 55	10 113	6 11	
South Carolina <sup>†</sup>	—	2 3	11 24	32 28	19 27	—	0 10	0 24	 85	141	—	1 2	9 15	4 8	1	
Virginia† West Virginia	_	0	24	20	27	2	1	6	16	26	_	0	1	0 1	2	
E.S. Central	2	9	33	141	57	2	3	7	17	36	_	4	23	7	7	
Alabama <sup>†</sup> Kentucky	_	1 4	5 15	22 76	17 7	2	0 1	0 4	17	4	_	1 0	8 1	4	4	
Mississippi	_	2	5	16	24	—	Ó	1	_	1	—	0	3	1	1	
Tennessee <sup>†</sup> W.S. Central	2 4	2 33	14 276	27 248	9 125	—	2 1	6 11	6	31 13	2	2 2	19 41	2 3	2 6	
Arkansas <sup>†</sup>	4	1	20	15	16	_	ò	6	2	11		0	14	1	—	
Louisiana Oklahoma	2	2 0	7 29	20 9	2 1	_	0 0	0 10	4	1	1	0 0	1 26	1	_2	
Texas <sup>†</sup>	2	28	232	204	106	—	0	1	_	1	1	1	6	1	4	
Mountain Arizona	5 2	14 2	31 10	183 25	253 67	2 N	2 0	9 0	24 N	11 N	_	1 0	3	1	3 1	
Colorado	1	3	12	64	54		0	0			_	0	1	_	_	
Idaho† Montana†	2	1 0	5 8	17 5	6 46	_	0 0	0 4	10	_	_	0 0	1	_	_	
Nevada <sup>†</sup>	_	0	7	6	4	_	0	5	_	_	_	0	2	_	_	
New Mexico <sup>†</sup> Utah	_	1 4	10 19	18 48	9 63	_	0 0	3 6	6	9	_	0 0	1	1	1 1	
Wyoming <sup>†</sup>	_	Ó	2	_	4	2	ŏ	4	8	2	—	õ	2	<u> </u>	<u> </u>	
Pacific Alaska	19	25 3	81 21	141 24	160 22	_	4 0	13 2	30 6	26 10	N	0 0	1 0	N	N	
California	_	7	23	13	53	_	3	12	6 24	16	_	0	1	_	_	
Hawaii Oregon†	1 1	0 3	3 16	6 45	3 38	_	0 0	0 2	_	_	N	0 0	0 1	Ν	N	
Washington	17	6	77	45 53	38 44	_	0	2	_	_	_	0	0	_	_	
American Samoa	—	0	0	—	_	Ν	0	0	Ν	Ν	Ν	0	0	Ν	Ν	
C.N.M.I. Guam	_	0	0	_	_	_	0	0	_	_	N	0	0	N	N	
Puerto Rico	—	0	0	—	_	_	1	5	10	11	N	0	0	Ν	N	
U.S. Virgin Islands		0	0	_		N	0	0	N	N	N	0	0	N	N	

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting year 2008 and 2009 are provisional. † Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(13th week)^		s	almonello	sis		Shig	a toxin-pr	oducing E	. coli (ST	EC)†		S	higellosis		
			vious				Prev						vious		
Reporting area	Current week	Med	veeks Max	Cum 2009	Cum 2008	Current week	52 w	eeks Max	Cum 2009	Cum 2008	Current week	52 w	eeks Max	Cum 2009	Cum 2008
United States	333	950	2,145	6,680	6,866	42	84	222	520	776	131	443	815	3,334	3,302
New England Connecticut Maine <sup>§</sup> Massachusetts New Hampshire Rhode Island <sup>§</sup> Vermont <sup>§</sup>	6  2 3 1	31 0 2 19 3 2 1	115 88 8 51 10 9 7	339 88 18 167 29 25 12	750 491 27 181 20 20 11	  	4 0 1 1 0 0	14 10 3 11 3 3 6	27 10 9 7 1	75 47 2 18 6 2		3 0 3 0 0 0	10 4 9 1 1 2	43 4 2 31 1 4 1	73 40 1 26 1 4 1
Mid. Atlantic New Jersey New York (Upstate) New York City Pennsylvania	37  24 1 12	91 9 27 22 28	177 29 64 54 78	718 58 204 184 272	836 200 172 215 249	2 2 	6 0 3 1 0	49 3 48 5 8	39 3 23 10 3	234 9 202 9 14	14 — — 14	51 16 9 12 8	96 38 35 35 28	548 154 43 106 245	339 82 76 153 28
<b>E.N. Central</b> Illinois Indiana Michigan Ohio Wisconsin	29 — 3 24 2	98 27 9 18 27 15	194 72 53 38 65 50	793 165 31 170 290 137	762 239 46 151 199 127	2 — 1 1	11 1 2 3 3	75 10 14 43 17 20	64 7 8 16 19 14	83 16 4 19 15 29	27 — — 25 2	82 17 7 5 42 7	128 35 39 24 80 33	703 117 9 72 432 73	686 226 208 15 162 75
W.N. Central Iowa Kansas Minnesota Missouri Nebraska <sup>§</sup> North Dakota South Dakota	22 7 4 6 5 —	53 9 7 11 13 5 0 3	148 16 29 69 48 41 10 22	562 69 57 118 96 146 9 67	430 70 42 123 115 48 6 26	7 2 2 1 2 	12 2 1 2 2 1 0 1	59 21 7 21 11 30 1 4	64 15 4 18 17 9 <u>-</u> 1	59 16 3 9 22 5 	6 1 2 3 	15 4 2 4 3 0 0 0	39 12 5 25 14 3 5	110 28 40 15 20 5 1 1	196 17 2 34 78 — 19 46
S. Atlantic Delaware District of Columbia Florida Georgia Maryland <sup>§</sup> North Carolina South Carolina <sup>§</sup> Virginia <sup>§</sup> West Virginia	108 — 66 15 3 17 3 4 —	250 2 0 97 43 14 28 18 20 3	456 9 4 174 86 36 106 55 89 8	1,906 7 793 297 129 386 126 140 28	1,687 20 13 858 197 111 178 148 117 45	11  6 -2 2  1	14 0 2 1 2 2 0 3 0	51 2 1 11 7 9 21 4 27 3	126 2 41 9 19 41 2 11 1	118 2 41 5 14 12 9 25 8	25 	55 0 13 17 3 4 7 5 0	100 1 34 48 12 27 32 59 3	519 5 110 121 78 103 41 56 5	726 1 245 281 17 25 135 16 2
E.S. Central Alabama <sup>§</sup> Kentucky Mississippi Tennessee <sup>§</sup>	5 1 4	60 16 10 14 15	140 49 18 57 62	349 98 78 59 114	408 141 68 84 115	2   2	5 1 1 0 2	12 3 7 2 6	27 4 5 1 17	49 25 8 2 14	5  - 5	33 6 3 2 19	67 18 24 18 48	185 38 23 5 119	436 117 44 136 139
<b>W.S. Central</b> Arkansas <sup>§</sup> Louisiana Oklahoma Texas <sup>§</sup>	22 6 1 15 —	139 11 17 15 93	1,118 40 50 36 1,057	377 74 65 90 148	489 61 90 62 276	5 1 	6 1 0 1 5	54 3 1 19 48	33 5 4 24	61 6 1 2 52	31 3  28	98 11 11 3 65	523 27 26 43 463	700 56 42 33 569	452 48 90 24 290
Mountain Arizona Colorado Idaho <sup>§</sup> Montana <sup>§</sup> Nevada <sup>§</sup> New Mexico <sup>§</sup> Utah Wyoming <sup>§</sup>	23 7 6 1 4 3 — 1	59 20 12 3 2 3 7 6	115 44 29 15 8 14 32 19 4	480 203 110 29 27 44 18 43 6	585 161 188 28 13 54 60 64 17	2 2       	11 1 2 0 1 1 0	39 5 18 15 3 6 9	72 8 44 6 2 1 6 4 1	69 16 13 7 3 8 2 1	8 7 1 — —	25 14 2 0 3 2 1 0	52 33 11 2 13 12 3 1	248 180 24 2 2 22 18 2 2 	148 63 18 2 46 13 3 3
Pacific Alaska California Hawaii Oregon <sup>§</sup> Washington	81 	114 1 84 5 7 12	530 4 516 15 20 155	1,156 10 874 66 83 123	919 12 728 46 67 66	11 3 8	9 0 6 0 1 2	60 1 39 2 8 44	68  51 1  16	28 1 21 2 3 1	15  13  2	31 0 27 1 1 2	83 1 75 3 10 28	278 2 221 5 17 33	246  211 11 13 11
American Samoa C.N.M.I. Guam Puerto Rico U.S. Virgin Islands		0 0 14 0	$\begin{array}{c} \frac{1}{2} \\ 40 \\ 0 \end{array}$	 58 	1 3 132 —		0 0 0 0	0 0 0 0		 		0 0 0 0	2 3 4 0	3 — — —	1 5 4 —

C.N.M.I.: Commonwealth of Northern Mariana Islands.

U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \* Incidence data for reporting year 2008 and 2009 are provisional. † Includes *E. coli* O157:H7; Shiga toxin-positive, serogroup non-O157; and Shiga toxin-positive, not serogrouped. § Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

	5	Streptococcal	diseases, inv	asive, group A		Streptococcus pneumoniae, invasive disease, nondrug resistant Age <5 years							
	Current	Prev 52 w		Cum	Cum	Current	Prev 52 w		Cum	Cum			
Reporting area	week	Med	Max	2009	2008	week	Med	Max	2009	2008			
United States	118	99	214	1,590	1,790	41	35	90	481	561			
New England	_	5	31	93	112	_	1	12	13	31			
Connecticut Maine <sup>§</sup>	_	0	26 3	23 6	9 10	_	0	11	_	1			
Massachusetts	_	3	7	39	74	—	1	3	9	26			
New Hampshire Rhode Island <sup>§</sup>	_	1 0	4	15 4	10 3	_	0 0	1 2	2	4			
Vermont§	_	ŏ	3	6	6	_	Ő	1	2	_			
Vid. Atlantic	17	18	34	290	372	4	3	25	58	64			
New Jersey New York (Upstate)	13	1 6	9 23	2 104	76 98	4	1 2	4 19	10 37	20 25			
New York City	_	4	12	60	77	_	0	23	11	19			
Pennsylvania	4	7	16	124	121	N	0	2	N	N			
E.N. Central Illinois	10	16 4	40 11	291 69	355 111	_2	6 1	11 5	70 9	104 31			
Indiana	_	3	19	41	42	_	Ö	5	4	12			
Michigan		3	9	49	66	1	1	5	21	28			
Ohio Wisconsin	7 3	4 1	14 10	99 33	90 46	1	1 0	5 2	28 8	16 17			
W.N. Central	22	5	37	136	142	10	2	11	43	35			
Iowa	_	0	0	—	_	—	0	0	_	_			
Kansas Minnesota	1 18	0 0	8 34	18 52	20 55	N 6	0 0	1 9	N 15	N 13			
Missouri	2	1	8	39	36	4	1	3	19	16			
Nebraska§	1	1	3	17	15	—	0	1	2	2			
North Dakota South Dakota	_	0 0	2 2	2 8	7 9	_	0 0	3 2	3 4	1 3			
S. Atlantic	44	21	33	370	362	8	6	14	100	115			
Delaware	_	0	1	6	5	_	0	0	_	_			
District of Columbia Florida	7	0 6	4 12	92	8 79	N 2	0 1	0 3	N 20	N 16			
Georgia	6	5	14	89	75	1	1	6	33	31			
Maryland <sup>§</sup> North Carolina	6 13	3 2	10 8	53 42	71 43	2 N	1 0	3 0	21 N	26 N			
South Carolina <sup>§</sup>	3	1	o 5	24	43 24	3	1	6	21	19			
Virginia <sup>§</sup>	8	3	10	53	42	_	0	3	1	20			
West Virginia	1	0	3	11	15	_	0	2	4	3			
E.S. Central Alabama <sup>§</sup>	6 N	4 0	9 0	74 N	54 N	1 N	2 0	6 0	17 N	29 N			
Kentucky	_	1	5	14	13	N	0	0	N	N			
Mississippi Tennessee§	N 6	0 3	0 7	N 60	N 41	1	0 1	3 6	17	7 22			
W.S. Central	14	10	58	156	142	14	6	36	91	71			
Arkansas <sup>§</sup>	2	0	2	6	2	1	0	3	9	3			
Louisiana Oklahoma	4	0 2	2 13	5 60	8 41	2	0	3 7	12 16	2 25			
Texas <sup>§</sup>	8	6	45	85	91	11	4	27	54	41			
Mountain	5	9	23	138	210	1	4	15	78	96			
Arizona Colorado	4 1	3 3	8 8	39 56	68 59	1	2 1	9 4	45 18	49 19			
Idaho§		0	2	3	59	_	0	4	2	19			
Montana <sup>§</sup>	Ν	0	0	N	N	N	0	0	N	N			
Nevada <sup>§</sup> New Mexico <sup>§</sup>	_	0 1	1 6	2 21	5 50	_	0 0	1 2	5	1 11			
Utah	_	1	6	16	17	_	0	4	8	15			
Wyoming§	—	0	1	1	3	_	0	1					
<b>Pacific</b> Alaska	_	3 0	8 4	42 5	41 10	1 1	1 0	5 4	11 8	16 10			
California	N	0	4	ъ N	N	N	0	0	8 N	N			
Hawaii	_	3	8	37	31	_	0	2	3	6			
Oregon <sup>§</sup> Washington	N N	0	0	N N	N N	N N	0 0	0	N N	N N			
American Samoa	_	0	12	_	_	N	ů 0	0	N	N			
C.N.M.I.	—	_	_	—	—	_	_	_	_	—			
Guam Puerto Rico	N	0 0	0 0	N	N	N	0 0	0 0	N	N			
J.S. Virgin Islands	IN	0	0			N	0	0	N	N			

C.N.M.I.: Commonwealth of Northern Mariana Islands.

C.N.M.L. Commonwealth of Normer Marana Islands.
U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.
\* Incidence data for reporting year 2008 and 2009 are provisional.
† Includes cases of invasive pneumococcal disease, in children aged <5 years, caused by *S. pneumoniae*, which is susceptible or for which susceptibility testing is not available (NNDSS event code 11717).
§ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

#### **MMWR**

	Streptococcus pneumoniae, invasive disease, drug resistant <sup>†</sup>															
			All ages				Aç	ged <5 yea	ars		Syphilis, primary and secondary					
		Prev 52 w	ious					vious veeks					/ious /eeks			
Reporting area	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	Current week	Med	Max	Cum 2009	Cum 2008	
United States	65	57	103	975	1,094	4	8	22	134	130	116	255	384	2,830	3,025	
New England	1	1	48	17	19	_	0	5	_	1	1	5	15	85	74	
Connecticut Maine <sup>§</sup>	_	0	48 2	3	7	_	0 0	5 1	_	_	_	1 0	5 2	21 1	3 2	
Massachusetts	_	0	0	_	—	_	0	0	_	_	1	4	11	52	60	
New Hampshire Rhode Island <sup>§</sup>	_	0 0	3 4	5 4	7	_	0 0	0 1	_	_	_	0 0	2 5	7 4	4 2	
Vermont§	1	0	2	5	5	_	0	1	_	1	_	0	2	_	3	
Mid. Atlantic New Jersey	4	4 0	14 0	46	104	1	0	3 0	9	8	17	33 4	51 10	434 49	429 61	
New York (Upstate)	1	1	6	18	16	1	0	2	5	2	1	2	8	24	27	
New York City Pennsylvania	3	1	5 10	1 27	44 44	_	0 0	0 2	4	6	16	23 5	37 11	300 61	261 80	
E.N. Central	11	9	28	157	240	_	1	6	22	28	17	26	47	216	373	
Illinois Indiana	<u>N</u>	0 2	0 19	N 19	N 85	N	0	0 3	N 2	N 10	2 8	5 2	14 10	36 39	118 36	
Michigan	1	0	3	7	6	—	0	1	_	1	5	4	18	62	33	
Ohio Wisconsin	10	7 0	18 0	131	149	_	1 0	4	20	17	2	11 1	27 4	66 13	172 14	
W.N. Central	4	2	8	36	81	2	0	2	9	4	2	7	14	73	113	
lowa Kansas	3	0 1	0 4		36	2	0 0	0	7	1	1	0 0	2 3	7 3	4 6	
Minnesota	_	0	0	_	—	—	0	0	—	—	_	2	6	15	29	
Missouri Nebraska <sup>§</sup>	1	1 0	4 0	21	43	_	0 0	1 0	_2	1	1	4 0	10 2	45 3	71 3	
North Dakota	_	0	2	4	_	—	0	0	_	_	—	0	0	—	—	
South Dakota S. Atlantic		0 22	2 51	 518	2 451	_	0 4	1 14		2 63	 39	0 59	1 197	678	 509	
Delaware	36	0	1	518	1	1	0	0	66	_	39	0	4	8	1	
District of Columbia Florida	N 18	0 14	0 36	N 332	N 239	N 1	0 3	0 13	N 47	N 34	 18	2 20	9 37	41 268	28 207	
Georgia	11	7	23	143	168	_	1	5	19	24	_	13	169	74	48	
Maryland <sup>§</sup> North Carolina	1 N	0 0	1 0	4 N	4 N	N	0	0	N	1 N	9 8	8 6	16 19	81 122	72 65	
South Carolina§	_	0	0	_	_	—	0	0	_	_	3	2	6	19	18	
Virginia <sup>§</sup> West Virginia	N 6	0 1	0 7	N 33	N 39	<u>N</u>	0 0	0 2	N	N 4	_	5 0	16 1	64 1	69 1	
E.S. Central	7	5	25	128	119		1	4	17	14	11	22	36	286	266	
Alabama§ Kentucky	N 2	0 1	0 6	N 33	N 25	N	0	0 2	N 4	N 4	_	8 1	17 10	99 17	120 14	
Mississippi	_	0	2	_	—	_	0	1	—	_	1	3	18	49	26	
Tennessee§	5	3 2	22 7	95 29	94 38	_	0 0	3 1	13 5	10 7	10	8	19 74	121 543	106 492	
W.S. Central Arkansas <sup>§</sup>	_	20	5	29 16	5	_	0	1	2	2	24 5	45 3	35	71	24	
Louisiana Oklahoma	N	1 0	6 0	13 N	33 N	N	0	1 0	3 N	5 N	1	10 1	33 7	48 14	107 22	
Texas <sup>§</sup>	_	Ő	Ő	_	_	_	Ő	Ő	_	_	18	28	40	410	339	
Mountain Arizona	2	2 0	7 0	42	41	_	0 0	3 0	6	_4	3	9 4	18 13	59 19	141 77	
Colorado	_	0	0	_	_	_	0	0	_	_	_	1	5	3	28	
Idaho§ Montana§	N	0	1	N	N	N	0 0	1 0	N	N	_	0	2 7	2	1	
Nevada§	2	1	4	19	20	_	0	1	3	1	3	1	7	25	22	
New Mexico <sup>§</sup> Utah	_	0 1	1 6	19	21	_	0 0	0 3	3	3	_	1 0	4 2	10	5 8	
Wyoming§	—	0	2	4	—	—	0	0	—	—	—	0	1	—	—	
Pacific Alaska	_	0 0	1 0	_2	1	_	0 0	1 0	_	1	_2	45 0	71 1	456	628	
California	N	0	0	Ν	N	N	0	0	N	N	2	41	65	417	565	
Hawaii Oregon <sup>§</sup>	N	0 0	1 0	2 N	1 N	N	0 0	1 0	N	1 N	_	0 0	3 3	10 8	8 5	
Washington	Ν	0	0	Ν	Ν	Ν	0	0	Ν	Ν	—	2	9	21	50	
American Samoa C.N.M.I.	N	0	0	N	N	N	0	0	N	N	_	0	0	_	_	
Guam	_	0	0	_	_	—	0	0	_	_		0	0		_	
Puerto Rico U.S. Virgin Islands	_	0 0	0 0	_	_	_	0 0	0 0	_	_	1	3 0	11 0	43	33	
5.5. Virgin Islanus		0	0				U	0				U	0			

TABLE II. (Continued) Provisional cases of selected notifiable diseases, United States, weeks ending April 4, 2009, and March 29, 2008 (13th week)\*

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Max \* Incidence data for reporting year 2008 and 2009 are provisional. \* Includes cases of invasive pneumococcal disease caused by drug-resistant *S. pneumoniae* (DRSP) (NNDSS event code 11720). \$ Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

(ISTI WEEK)						West Nile virus disease <sup>†</sup>										
		Varic	ella (chick	enpox)		Neuroinvasive Nonneuroinvasive§										
			vious					ious					vious			
Reporting area	Current week	52 v Med	weeks Max	Cum 2009	Cum 2008	Current week	52 w	eeks Max	Cum 2009	Cum 2008	Current week	52 w	eeks Max	Cum 2009	Cum 2008	
United States	171	437	1,015	4,661	8,559		1	74		2000		2	77		2000	
New England	4	13	29	85	272	_	0	2	_	_	_	0	1	_	_	
Connecticut	—	0	0	—		_	0 0	2	_	_	—	0 0	1	—	—	
Maine <sup>¶</sup> Massachusetts	_	3 0	11 1	_	101	_	0	0 1	_	_	_	0	0	_	_	
New Hampshire	4	4	12	58	93	—	0	Ö	_	_	_	0	Ō	_	_	
Rhode Island <sup>¶</sup> Vermont <sup>¶</sup>	_	0 4	0 17	27	 78	_	0	1 0	_	_	_	0	0	_	_	
Mid. Atlantic	29	44	83	465	753	_	Ő	8	_	_	_	0 0	4	_	_	
New Jersey	N	0	0	N	N	—	0	2	—	—	—	0	1	—	—	
New York (Upstate) New York City	N	0	0	N	N	_	0	5 2	_	_	_	0	2 2	_	_	
Pennsylvania	29	44	83	465	753	—	õ	2	—	—	—	õ	1	—	—	
E.N. Central	63	149	312	2,054	1,894	—	0	8	_	—	—	0	3	—	—	
Illinois Indiana	_2	39 0	73 5	535 21	151	_	0 0	4 1	_	_	_	0 0	2 1	_	_	
Michigan	22	57	116	651	847	_	0	4	_	_	_	0	2	_	_	
Ohio Wisconsin	36 3	46 5	106 50	762 85	814 82	_	0 0	3 2	_	_	_	0 0	1	_	_	
W.N. Central	22	21	72	402	424	_	0	6	_	1	_	0	21	_	_	
Iowa	N	0	0	N	N	_	0	2	—	—	_	0	1	_	_	
Kansas Minnesota	6	5 0	22 0	87	221	_	0	2 2	_	1	_	0	3 4	_	_	
Missouri	16	12	51	279	184	_	ő	3	_	_	_	ŏ	1	_	_	
Nebraska <sup>¶</sup> North Dakota	N	0 0	0 39	N	N 4	_	0	1	_	_	_	0	6	_	_	
South Dakota	_	0	39 4	36	4 15	_	0	2 5	_	_	_	0	11 6	_	_	
S. Atlantic	48	73	163	704	1,592	_	0	3	_	_	_	0	4	_	_	
Delaware District of Columbia	—	1 0	5 3	1	5 7	_	0	0 1	_	—	_	0	1	—	_	
Florida	39	29	68	469	568	_	0	2	_	_	_	0	0	_	_	
Georgia	N	0	0	N	N	—	0	1	—	—	—	0	1	—	—	
Maryland <sup>¶</sup> North Carolina	N N	0	0	N N	N N	_	0	2 0	_	_	_	0	3 0	_	_	
South Carolina <sup>¶</sup>	_	9	67	58	268	—	Ō	Ō	_	_	_	Ō	1	—	_	
Virginia <sup>¶</sup> West Virginia	9	17 11	60 33	28 148	518 226	_	0 0	0 1	_	_	_	0 0	1 0	_	_	
E.S. Central		11	101	140	342	_	0	7	_	_	_	0	9	_	2	
Alabama¶		11	101	16	336	_	0	3	_	_	_	0	2	_	—	
Kentucky Mississippi	N	0 0	0 1	N 1	N 6	_	0	1 4	_	_	_	0	0 8	_	1	
Tennessee <sup>¶</sup>	Ν	ŏ	0	Ň	Ň	_	ŏ	2	_	_	_	Ő	3	_	1	
W.S. Central	_	91	435	492	2,509	_	0	8	_	_	_	0	7	_	_	
Arkansas <sup>¶</sup> Louisiana	_	5 1	61 5	19 15	223 30	_	0	1 3	_	_	_	0	1 5	_	_	
Oklahoma	Ν	0	0	N	N	—	0	1	_	_	—	0	1	—		
Texas <sup>¶</sup>		79	422	458	2,256	_	0	6	_	_	_	0	4	_	_	
Mountain Arizona	_4	33 0	89 0	402	742	_	0	12 10	_	1	_	0	22 8	_	_	
Colorado	4	14	44	181	307	_	0	4	_	_	_	0	10	_	_	
Idaho¶ Montana¶	N	0 5	0 27	N 66	N 112	_	0	1	_	_	_	0	6	_	_	
Nevada <sup>¶</sup>	Ν	0	0	Ν	Ν	_	0	2	_	_	_	Õ	3	_	_	
New Mexico <sup>¶</sup> Utah	—	2	10	33	88	_	0	1	_	—	—	0	1	—	—	
Wyoming <sup>¶</sup>	_	11 0	53 4	122	231 4	_	0 0	2 0	_	_	_	0 0	5 2	_	_	
Pacific	1	3	8	40	31	_	0	38	_	_	_	0	23	_	_	
Alaska California	—	2 0	6 0	25	10	_	0 0	0 37	_	_	_	0 0	0 20	_	_	
Hawaii	1	1	4	15	21	_	0	0	_	_	_	0	20	_	_	
Oregon <sup>¶</sup>	Ň	0	0	N	N	—	0	2	—	—	—	0	4	—	—	
Washington American Samoa	N N	0	0	N N	N N	_	0 0	1 0	_	_	_	0 0	1 0	_	_	
C.N.M.I.	IN	_	_		—	_	_	_	_	_	_	_	_	_	_	
Guam	—	1	17		17	—	0	0	—	—	—	0	0	—	—	
Puerto Rico U.S. Virgin Islands	_	9 0	29 0	82	145	_	0 0	0 0	_	_	_	0 0	0 0	_	_	
		U					U	0				U	0			

C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. —: No reported cases. N: Not notifiable. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum.

\* Incidence data for reporting year 2008 and 2009 are provisional.

<sup>+</sup> Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for California serogroup, eastern equine, Powassan, St. Louis, and western equine diseases are available in Table I.

<sup>§</sup> Not notifiable in all states. Data from states where the condition is not notifiable are excluded from this table, except starting in 2007 for the domestic arboviral diseases and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://www.cdc.gov/epo/dphsi/phs/infdis.htm.
<sup>¶</sup> Contains data reported through the National Electronic Disease Surveillance System (NEDSS).

#### TABLE III. Deaths in 122 U.S. cities,\* week ending April 4, 2009 (13th week)

All causes, by age (years)					-			All ca	uses, by	age (yea	rs)				
Reporting area	All Ages	<u>≥</u> 65	45–64	25–44	1–24	<1	P&I <sup>†</sup> Total	Reporting area	All Ages	≥65	45–64	25–44	1–24	<1	P&I <sup>†</sup> Total
New England	539	373	106	40	9	11	62	S. Atlantic	1,201	759	269	101	40	30	64
Boston, MA	137	82	32	15	4	4	17	Atlanta, GA	152	87	41	16	7	1	4
Bridgeport, CT	30	23	6	1	_		5	Baltimore, MD	167	103	42	10	8	4	13
Cambridge, MA	15	13	1	-	_	1	2	Charlotte, NC	123	71	31	13	3	5	12
Fall River, MA Hartford, CT	23 50	17 31	5 9	1 9	1	_	1 4	Jacksonville, FL Miami, FL	131 106	85 76	24 18	12 6	5 5	5 1	2 4
Lowell, MA	26	21	9 4	9 1	_	_	4	Norfolk, VA	57	35	13	6	2	1	4
Lynn, MA	20	5	-	1	1	_	1	Richmond, VA	40	22	10	5	1	2	2
New Bedford, MA	31	23	7	1	_	_	1	Savannah, GA	63	45	13	3	2		5
New Haven, CT	Ŭ	Ū	Ů	Ů	U	U	Ŭ	St. Petersburg. FL	65	39	12	9	_	5	4
Providence, RI	53	38	12	2	_	1	4	Tampa, FL	209	142	48	11	5	3	13
Somerville, MA	3	3	_	_	_	_	_	Washington, D.C.	71	42	14	8	2	3	2
Springfield, MA	45	31	7	3	1	3	5	Wilmington, DE	17	12	3	2	_	—	3
Waterbury, CT	42	28	9	3	1	1	4	E.S. Central	862	549	209	66	18	20	70
Worcester, MA	77	58	14	3	1	1	17	Birmingham, AL	167	110	35	10	6	6	15
Mid. Atlantic	1,954	1,365	432	81	34	41	115	Chattanooga, TN	93	65	23	4	1	_	1
Albany, NY	43 27	34 21	5 5	1 1	3	—	2	Knoxville, TN	103 51	70 32	21 14	7 3	1 1	4 1	5 7
Allentown, PA Buffalo, NY	76	52	16	1	3	4	7	Lexington, KY Memphis, TN	159	32 99	37	14	3	6	20
Camden, NJ	30	21	5	2	1	4	1	Mobile. AL	103	99 66	28	7	2		20
Elizabeth, NJ	11	7	3	1	_	_	1	Montgomery, AL	40	21	13	4	1	1	2
Erie, PA	45	33	9	2	_	1	5	Nashville, TN	146	86	38	17	3	2	11
Jersey City, NJ	53	37	11	4	1	_	3	W.S. Central	1,397	885	349	92	35	36	92
New York City, NY	1,032	718	243	42	13	15	61	Austin, TX	89	56	21	9	1	2	4
Newark, NJ	34	11	11	7	—	5	3	Baton Rouge, LA	45	40	3	2	—	_	_
Paterson, NJ	12	3	6	1	_	2	2	Corpus Christi, TX	54	41	9	3	1	_	5
Philadelphia, PA	153	90	43	10	5	5	9	Dallas, TX	191	116	46	10	7	12	15
Pittsburgh, PA§	42	33	7	1	1	—	4	El Paso, TX	92	61	22	6	2	1	6
Reading, PA	32	30	2	2	4	_	2	Fort Worth, TX	U	U	U	U	U	U	U
Rochester, NY Schenectady, NY	163 22	122 16	32 4	2	4	3	8 3	Houston, TX Little Rock, AR	435 94	257 57	120 26	30 7	17 2	11 2	21 3
Scranton, PA	42	30	11	2 1	_	_	1	New Orleans, LA	94 U	57 U	20 U	ú	Ű	Ű	U
Syracuse, NY	75	61	7	_	3	4	1	San Antonio, TX	226	149	52	17	2	6	18
Trenton, NJ	21	14	4	2	_	1		Shreveport, LA	59	43	11	2	2	1	8
Utica, NY	19	15	3	1	_	_	1	Tulsa, OK	112	65	39	6	1	1	12
Yonkers, NY	22	17	5	_	_	_	1	Mountain	1,126	749	263	69	24	21	71
E.N. Central	2,012	1,364	449	127	35	37	166	Albuquerque, NM	113	74	24	9	4	2	11
Akron, OH	60	42	15	1	—	2	1	Boise, ID	66	44	11	8	2	1	3
Canton, OH	39	29	_4	5	1	_	4	Colorado Springs, CO	80	57	14	5	2	2	_
Chicago, IL	300	190	72	26	6	6	30	Denver, CO	92	64	20	6	1	1	5
Cincinnati, OH	87	57	18 52	5 8	3 5	4 3	7 17	Las Vegas, NV	280	175 25	81 8	16 1	5	3 1	24 5
Cleveland, OH Columbus, OH	235 189	167 128	52 41	0 14	1	5	16	Ogden, UT Phoenix, AZ	35 120	25 70	0 34	4	6	6	5
Dayton, OH	138	96	26	12	3	1	16	Pueblo, CO	39	27	9	2	1	_	5
Detroit, MI	137	74	41	13	6	3	7	Salt Lake City, UT	113	74	28	6	1	4	7
Evansville, IN	37	27	8	1	ĩ	_	1	Tucson, AZ	188	139	34	12	2	1	6
Fort Wayne, IN	70	56	10	3	_	1	9	Pacific	1,652	1,162	334	100	25	31	164
Gary, IN	27	12	11	2	2	—	1	Berkeley, CA	10	7	3	—	—	_	2
Grand Rapids, MI	60	46	12	—	_	2	5	Fresno, CA	100	66	18	13	1	2	7
Indianapolis, IN	189	119	44	19	3	4	15	Glendale, CA	28	23	3	2			8
Lansing, MI	48	31	13	4	_		4	Honolulu, HI	81	63	8	7	1	2	8
Milwaukee, WI	94	62	24	5	2	1	13	Long Beach, CA	65	46	13	3	2	1	9
Peoria, IL	45	35	7	2	1	1	7 3	Los Angeles, CA Pasadena, CA	262	167	66 4	19	3	7	29
Rockford, IL South Bend, IN	62 47	44 41	15 6	2	_	_	3	Pasadena, CA Portland, OR	21 99	15 71	4 17	2 5	2	4	1 6
Toledo, OH	47 91	62	0 21	5	_	3	6	Sacramento, CA	99 208	153	45	5 9	2 1	4	26
Youngstown, OH	57	46	9		1	1	3	San Diego, CA	145	97	32	10	2	4	14
W.N. Central	657	432	151	49	13	11	43	San Francisco, CA	96	62	23	5	3	3	11
Des Moines, IA	77	53	16	5	1	2	4	San Jose, CA	203	142	44	10	3	4	20
Duluth, MN	25	18	5	1	1	_	3	Santa Cruz, CA	36	27	5	4	_	_	2
Kansas City, KS	26	18	5	1	2	_	5	Seattle, WA	117	86	22	2	5	2	8
Kansas City, MO	96	52	23	15	5	1	3	Spokane, WA	66	51	11	2		2	8
Lincoln, NE	52	37	10	5	_	—	1	Tacoma, WA	115	86	20	7	2	_	5
Minneapolis, MN	76	50	16	7	1	2	10	Total <sup>¶</sup>	11,400	7,638	2,562	725	233	238	847
Omaha, NE	85	62	19	1	2	1	9								
St. Louis, MO	97	55	28	9	1	3	5								
St. Paul, MN	58	39	17	2	_		2								
Wichita, KS	65	48	12	3		2	1	1							

U: Unavailable. —:No reported cases. \* Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of >100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included.

<sup>†</sup> Pneumonia and influenza.

§ Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. <sup>1</sup> Total includes unknown ages.

The *Morbidity and Mortality Weekly Report (MMWR)* Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format. To receive an electronic copy each week, visit *MMWR*'s free subscription page at *http://www.cdc.gov/mmwr/mmwrsubscribe.html*. Paper copy subscriptions are available through the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone 202-512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Data are compiled in the National Center for Public Health Informatics, Division of Integrated Surveillance Systems and Services. Address all inquiries about the *MMWR* Series, including material to be considered for publication, to Editor, *MMWR* Series, Mailstop E-90, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333 or to *mmwrq@cdc.gov.* 

All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of these sites. URL addresses listed in *MMWR* were current as of the date of publication.

☆ U.S. Government Printing Office: 2009-523-019/41166 Region IV ISSN: 0149-2195